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   The important thing is to never stop questioning 
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ABSTRACT 
 
Embryonic development and cancer formation appear quite different from each other at first glance, 
yet they share common characteristics such as the reliance on certain signalling pathways. The 
Hedgehog (HH) and WNT signalling cascades play key roles in a variety of developmental processes 
where deregulation of these pathways result in a diversity of birth defects. In adult tissue, they are 
crucial for homeostasis and repair. Therefore, tight regulation of these pathways is of utmost 
importance, since aberrant activation can lead to numerous types of cancer. Suppressor of fused 
(SUFU) is an essential negative regulator of the HH pathway, and consequently pivotal for embryonic 
development such that Sufu-/- embryos die at around E9.5. The leucine-rich repeat containing G-
protein-coupled receptor 5 (LGR5), a WNT target gene, acts as a co-receptor in WNT signalling, and 
is up-regulated in basal cell carcinoma (BCC). Additionally, Lgr5 is a marker for adult stem cells in 
various tissues. 
In Paper I, we set out to explore the role of SUFU in lineage differentiation processes during early 
embryonic development, using mouse embryonic stem cells (mESC). Sufu-/- mESCs expressed typical 
pluripotency markers and showed characteristic morphology demonstrating that mESCs lacking Sufu 
can be kept in an undifferentiated state. Upon embryoid body formation in vitro and teratoma 
development in vivo, Sufu-/- mESCs exhibited limited differentiation capacity, with cartilage and bone 
completely missing in vivo. This result highlights the importance of HH signalling and in particular 
SUFU for regulating cell fate specification processes.  
In Paper II, we generated a hypomorphic Sufu allele and investigated the effects of significantly 
reduced SUFU levels on embryonic development in vivo. Sufu hypomorphic (Sufuhypo/hypo) embryos 
were viable up to E18.5 and showed a diverse range of developmental defects. Remarkably, despite 
the importance of HH signalling in skin development and BCC formation, Sufuhypo/hypo skin remained 
unaffected and did not show signs of hyperplasia or defects in epidermal differentiation. In stark 
contrast, bone development was severely impaired affecting numerous skeletal structures. Our 
findings further strengthen the role of SUFU in bone development, and demonstrate that tissues 
require different levels of SUFU for accurate development. 
In Paper III, we developed a transgenic mouse line in which expression of human (hu) LGR5 in basal 
cells of the skin could be reversibly controlled. We discovered that activation of huLGR5 during 
embryo development, with sustained expression after birth, affected skin development and 
homeostasis. Mice exhibited a sparse fur coat, hyperplasia of the interfollicular epidermis, and 
accelerated sebaceous gland maturation. However, no tumour formation was observed. Remarkably, 
the observed phenotype could be reversed when expression was stopped during early adulthood. 
Interestingly, induction of huLGR5 in juvenile mice did not result in any apparent phenotypic 
changes. 
In the preliminary study, we investigated the capacity of Sufu-/- hair follicle (HF) stem cells to initiate 
tumour formation. We unveiled that conditional inactivation of Sufu in Lgr5-expressing cells in 
juvenile or adult mice did not suffice to induce changes in the HF, or tumour formation. No changes 
were observed up to 80 weeks after Sufu deletion, and could furthermore not be provoked by 
wounding. This indicates that the level of HH signalling activity necessary for inducing skin changes 
is not achieved by deleting Sufu in the HF. 
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1 INTRODUCTION 
 
1.1 THE HEDGEHOG SIGNALLING PATHWAY 
The Hedgehog (HH) signalling cascade was originally identified in Drosophila as a segment 
polarity gene [1] and components of the pathway were subsequently discovered in 
vertebrates, including mammals. HH signalling plays a fundamental role in almost every 
aspect of animal development. It is essential for embryogenesis, governing various processes 
including cell proliferation, differentiation, and tissue patterning [2]. Furthermore, it is 
important for adult tissue homeostasis, implicated in stem cell maintenance and tissue repair 
[3]. Deregulation of the pathway during embryonic development leads to congenital 
malformations [4] and persistent activation in adult tissues is involved in several types of 
cancer [5,6]. HH signalling in developmental defects and cancer is described in more detail in 
section 1.5. Mammalian HH signalling is dependent on the primary cilium [7], a cellular 
organelle present on most vertebrate cells functioning as sensory antenna for signals [8]. The 
main pathway components comprise of the 12-span transmembrane receptor Patched 
(PTCH), which in the absence of a ligand represses Smoothened (SMO), a member of the G 
protein-coupled receptor (GPCR) superfamily, thereby preventing downstream signalling. In 
this OFF state, Suppressor of Fused (SUFU) binds to the GLI zinc finger transcription factors 
and regulates their activity in various ways, leading to impediment of target gene 
transcription. HH signalling is initiated by the binding of a ligand to the PTCH receptor, 
relieving its inhibitory function on SMO. As a consequence, GLI is released from SUFU and 
translocates into the nucleus inducing the activation of target genes. This simplified 
description highlights the main events within the signalling cascade (Figure 1). However, the 
HH pathway is much more complex involving many other interacting factors [6,9-12].  
 
1.1.1 Regulation of HH signalling at the membrane 
In mammals, three different HH ligands exist, Sonic (SHH), Indian (IHH), and Desert (DHH) 
hedgehog, which act as morphogens during development [13]. The HH proteins are 
synthesised as precursors and undergo auto-proteolytic cleavage and post-translational 
modifications prior to their secretion. HH proteins initiate signal transduction mainly by 
binding to PTCH [14]. Two Ptch genes exist, translating into PTCH1 and PTCH2 proteins. 
Whereas PTCH1 is expressed throughout the embryo, PTCH2 is primarily found in skin and 
spermatocytes [15]. Binding of the HH ligand to PTCH results in internalisation and 
degradation of the receptor and ligand [16]. This not only leads to removal of PTCH from the 
cell surface thus relieving pathway repression, but also limits access to HH ligand, providing 
a negative feedback loop. Besides PTCH, several other cell surface receptors modulate the 
pathway activation [17]. CAM-related/downregulated by oncogenes (CDO), brother of CDO 
(BOC) as well as growth arrest-specific 1 (GAS1) are co-receptors that bind to HH ligands 
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and promote HH signalling. Hedgehog-interacting protein (HHIP) on the contrary acts as a 
negative regulator, likely through competition with PTCH for ligand binding, thus limiting its 
diffusion. As PTCH and HHIP are target genes of the pathway, they provide a negative 
feedback loop not only inhibiting response in the cell that expresses them but also restricts 
availability of HH ligand for other cells.  
In the absence of HH ligand, PTCH is enriched in the primary cilium, preventing SMO 
ciliary accumulation [18]. Although it is not yet known in detail how PTCH exerts its 
inhibitory function on SMO, the current view suggests that PTCH does not physically interact 
with SMO, but rather regulates the transport of small molecules that agonise or antagonise 
SMO. Vitamin D3 derivatives [19] and oxysterols [20] have been suggested as endogenous 
SMO modulators, inhibiting or activating SMO, respectively. Additionally, the phospholipid 
phosphatidylinositol-4 phosphate (PI4P) has been implicated in activation of SMO, 
furthermore PTCH was demonstrated to limit the levels of PI4P [21]. Despite such recent 
insights, the exact mechanisms of SMO regulation by PTCH still remain unclear.  
 
 
Figure 1: Simplified overview of the hedgehog signalling pathway 
(Left panel) In the absence of HH ligand, PTCH represses SMO and thus prevents downstream 
signalling. In this OFF state SUFU binds to the GLI transcription factors and facilitates their processing 
into a repressor form (GLIR). (Right panel) Ligand binding to the PTCH receptor relieves SMO from 
PTCH-mediated inhibition. Consequently, SMO enters the primary cilium and triggers dissociation of 
SUFU-GLI complexes, allowing GLI to enter the nucleus and initiate target gene transcription.  
 
1.1.2 Signalling downstream of SMO 
Upon ligand binding to PTCH, SMO becomes phosphorylated, leading to a conformational 
switch, and moves into the primary cilium [6,9,11,12]. Ultimately, SMO activation results in 
the transcription of HH target genes mediated by the GLI transcription factors. Three GLI 
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proteins have been identified in mammals: GLI1, GLI2 and GLI3. All GLI proteins contain a 
C-terminal activation domain and GLI2 and GLI3, which are the primary effectors of the 
pathway, harbour an additional N-terminal repressor domain. Hence, they can exert both 
activating and inhibitory functions. While GLI2 is mainly considered as an activator of the 
pathway, GLI3 is responsible for suppressing target gene transcription. GLI1, itself a HH 
response gene, lacks the N-terminal repressor domain thus can only act as a transcriptional 
activator, amplifying the signal. In the absence of HH ligand, full-length (FL) GLI2 and GLI3 
proteins become phosphorylated, followed by ubiquitination and proteasomal processing, 
generating their shorter repressor forms (GLIR). SUFU forms a complex with GLI proteins 
and regulates their activity in various ways, discussed in more detail in section 1.1.5. Pathway 
activation through ligand binding leads to dissociation of the SUFU-GLI complexes and 
transport of the released GLIFL proteins to the nucleus, where they initiate transcription of 
target genes.  
 
1.1.3 HH target genes 
HH signalling activation leads to the expression of many genes involved in variety of 
processes including proliferation, cell survival, and feedback mechanisms [22-25]. The list of 
direct and indirect target genes is long and dependent on the cell type in which downstream 
HH signalling is activated, so that only the most frequently regulated genes will be mentioned 
here. Ptch1 and Ptch2 as well as Hhip, are up-regulated in response to HH signalling, 
whereas transcription of the co-receptors Cdo, Boc and Gas1 is inhibited resulting in a 
negative feedback loop. On the contrary, Gli1 expression is initiated upon HH pathway 
activation leading to amplification of the signal. FoxA2 was the first neural-specific GLI 
target gene identified [26] and in turn induces expression of Shh [27]. Additional targets of 
the pathway include cyclin D1, cyclin D2 and cyclin E, which drive cell-cycle progression. 
Expression of Bcl-2, involved in cell survival, is increased upon pathway activation and HH 
signalling also regulates genes important for epithelial-mesenchymal transition such as Snail 
[22].  
 
1.1.4 Primary cilium in HH signalling 
The primary cilium is required for HH signalling activation in homeostatic conditions [7]. In 
the absence of HH ligand, PTCH is localised at the base of the cilium preventing entry of 
SMO [18]. Upon binding of HH ligand to the PTCH receptor, SMO moves into primary 
cilium and, according to a recent study, binds to the EVC and EVC2 proteins in a distinct 
compartment of the cilium called the EvC zone [28]. This association was shown to be 
required for downstream signalling of SMO as a loss of EVC2 impaired pathway activation. 
Entry of SMO into the primary cilium is followed by accumulation of both GLI and SUFU, 
along with subsequent dissociation of SUFU-GLI complexes. It is not yet understood how 
SMO activity leads to liberation of GLI from SUFU. However, the kinesin protein KIF7 has 
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been implicated in the regulation and localisation of GLI proteins and may promote SUFU-
GLI dissociation [29-33].  
Recent studies have shown that the lipid composition of ciliary membranes influences HH 
pathway activation [34,35], demonstrating that the function of the primary cilium extends 
beyond its role as a mere physical location for HH signalling components. While PI4P was 
found in the ciliary membrane, the base of the cilia mainly contained PI(4,5)P2 
(phosphatidylinositol 4,5-bisphosphate). This differential distribution was maintained by the 
phosphatase Inpp5e, while loss of Inpp5e resulted in accumulation of PI(4,5)P2 in the ciliary 
membrane. As a consequence, Gpr161, considered a negative regulator of the pathway, 
accumulated in the primary cilium preventing downstream signalling.  
 
1.1.5 The role of SUFU in HH signalling 
SUFU is a negative regulator of the HH pathway that acts downstream of SMO and regulates 
GLI activity. Sufu-/- embryos die around E9.5 with a similar phenotype as seen in Ptch1-/- 
embryos and display constitutive pathway activation [36-38]. SUFU is able to bind all three 
GLI proteins [39-43] and previous studies suggested that SUFU interacts with GLI proteins 
in a head-to-tail manner, with the SUFU C-terminal region recognising the SYGH core motif 
in the N-terminus of GLI [42-45]. However, structural studies on SUFU-GLI complexes 
revealed that both SUFU N- and C-terminal regions bind simultaneously to the SYGH core 
motif [46].  
There are several ways SUFU can regulate GLI proteins. This includes preventing GLI 
translocation into the nucleus, possibly by anchoring GLIs in the cytoplasm or covering its 
nuclear localisation sequence (NLS) [39]. Along these lines, a recent study has identified a 
non-typical NLS (PY-NLS) in the N-terminal domain of GLI, which is masked by SUFU, 
hence prohibiting GLIs nuclear entry [47]. SUFU has also been found to interact with nuclear 
proteins and to recruit a co-repressor complex inhibiting transcriptional activity of GLI [48-
50], suggesting that SUFU-mediated regulation is not restricted to the cytoplasm. This 
hypothesis was further strengthened by recent findings showing that upon SHH induction, 
SUFU accompanied GLI1 into and GLI3 out of the nucleus [51]. Furthermore, SUFU-GLI 
complexes were found at GLI-binding sites, and SHH activation reduced the presence of the 
SUFU associated co-repressor complex [48,51]. Recently, a SUFU binding sequence located 
at the C-terminus of GLI has been implicated in differential regulation of GLI [52]. While 
binding of SUFU to the N-terminal region of GLI, containing the SYGH core motif, resulted 
in its cytoplasmic retention, the association to the C-terminal region inhibited the activity of 
GLI in the nucleus. 
In the absence of a HH signal, GLI2 and GLI3 proteins are converted to their transcriptional 
repressor forms (GLIR) [53,54], a process that is regulated by SUFU [55-58]. SUFU 
stimulates phosphorylation of GLI3 by the GSK3β kinase, which is necessary for generation 
of GLI3R [57]. Furthermore, SUFU is required for GLI3 proteasomal processing mediated by 
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SPOP, a substrate-binding adaptor for the cullin3-based ubiquitin E3 ligase [55]. In the 
absence of SUFU, GLI2 and GLI3 protein levels are however greatly reduced, demonstrating 
on the one hand that SPOP-mediated degradation of GLI2 and GLI3 is independent of SUFU 
while conversely, indicates that SUFU is also required for stabilisation of GLI proteins. In 
agreement with this, SUFU was shown to stabilise GLI2 and GLI3 full-length proteins, but 
not their repressors [55,58,59]. The threonine 398 (Thr398) residue of SUFU was identified to 
be crucial for regulating GLI3 but not GLI2 stabilisation and processing [60]. The 
mechanisms that regulate GLI1 stability differ and are dependent on Numb/Itch-mediated 
ubiquitination and degradation [61], which is antagonised by SUFU [62]. 
As discussed in section 1.1.4, the primary cilium has a central role in the HH signalling 
pathway. Although SUFU and GLI co-localise in the ciliary tip, the inhibitory function of 
SUFU is independent of cilia [59]. Dissociation of the SUFU-GLI complexes, a prerequisite 
for pathway activation, occurs on the other hand at the tip of the primary cilium [56,63]. The 
exact mechanisms of how GLI is released from SUFU are not known, however, KIF7 plays 
an important role in this step [29,30,32,33]. SUFU and KIF7 were found to have 
antagonising and cooperative functions in regulating HH pathway activation [29,30,32]. 
KIF7 is believed to promote dissociation of SUFU-GLI complexes at the tip of the primary 
cilium and to restrict the inhibitory function of SUFU on GLI proteins. However, in the 
absence of SUFU, KIF7 represses GLI-dependent transcription.  
SUFU stabilisation itself is governed by dual phosphorylation through protein kinase A 
(PKA) and GSK3β at the two serine residues Ser-342 and Ser-346, preventing its degradation 
[64]. Additionally, dual phosphorylation at these sites promotes SUFU's nuclear localisation 
[51]. Recent insights in to the structure of SUFU have unveiled the presence of an 
intrinsically disordered region (IDR), a flexible loop with no fixed structure [46]. 
Remarkably, the IDR harbours amino-acid residues that can serve as targets for these kinases, 
suggesting a function for the IDR in SUFU regulation [46]. The E3 ubiquitin ligase Fbxl17 
has recently been identified to bind to SUFU and promote its degradation [65]. This 
interaction was impaired by SUFU phosphorylation at Ser-342 and Ser-346, corroborating the 
stabilising function these phosphorylation events are described to have [64,65]. Additional 
regulators of SUFU include the right open reading frame kinase 3 (RIOK3), which modulates 
SUFU's subcellular distribution [66] and the NIMA (never in mitosis A)-related expressed 
kinase 2A (Nek2A), which was found to phosphorylate and thereby stabilise SUFU [67]. 
 
1.2 PRE-IMPLANTATION DEVELOPMENT AND GASTRULATION 
Embryogenesis starts with the fertilisation of the oocyte by the sperm, resulting in a one-cell 
embryo known as a zygote [68-72]. During the pre-implantation period the zygote travels 
along the oviduct to the uterus, while undergoing several rounds of cleavage divisions, 
successively generating an increasing number of cells. This is succeeded by compaction and 
polarisation, and 3.5 days after fertilisation the mouse embryo has generated two distinct 
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lineages, the inner cell mass (ICM) and the trophectoderm (TE) and is now considered an 
early blastocyst. Embryonic stem cells (ESC) are derived from the ICM of the embryonic (E) 
3.5 day blastocyst [73,74] and a description of ESCs and their use in research will follow in 
section 2.1. At E4.5, before implantation, the ICM has undergone differentiation resulting in 
the epiblast lineage and primitive endoderm (PE) [68-71]. While TE and PE contribute to the 
extraembryonic tissues such as placenta and yolk sac, only the epiblast cells will give rise to 
the foetus itself. At around this stage the blastocyst has reached the uterus and the zona 
pellucida (a protective acellular layer surrounding the pre-implantation embryo) breaks down, 
releasing the blastocyst, thus enabling attachment to the uterine wall. This process, called 
hatching, is independent of the uterine environment and also occurs in vitro, a fact utilised in 
the derivation of ESCs [75].  
Shortly after implantation the embryo grows by cell division, adopts a cylindrical shape, 
known as an egg cylinder, and ultimately reaches the stage of gastrulation, at which time the 
embryonic body plan is established [72,76-79]. During the complex process of gastrulation 
the embryo is remodelled and epiblast cells are allocated to the primary germ layers: 
ectoderm, mesoderm, and definitive endoderm, which are the progenitors of all foetal tissue 
lineages. The ectoderm gives rise to the central and peripheral nervous system and the 
epidermis, the mesoderm develops into dermis, muscle, cartilage, bone, heart, and 
haematopoietic cells, while the endoderm generates lung, liver, and pancreas and forms cells 
of the epithelial lining of the respiratory and digestive tract [78,79]. Cell populations assigned 
to form a specific organ are brought into proximity and differentiate, a process during which 
cells acquire a more specialized cell fate. This is accomplished by activation of lineage-
specific genes and affected by anatomical position of the cells, and cellular interactions 
through specific signalling pathways [72,77,78]. Main signalling pathways involved in 
primary germ layer differentiation are the TGF-β family, Wnt, and FGF families. During 
further lineage specification HH signalling assumes a critical role and induces a large number 
of developmental processes required for patterning of the central nervous system [80], 
development of the gastrointestinal tract and other organs [81].  
 
1.3 THE SKIN 
The skin is the largest organ in the mammalian body. Its main function is to prevent extensive 
water loss, thus serving as a permeability barrier. Furthermore, it protects from external 
injuries such as mechanical trauma, pathogens, UV radiation, but also regulates body 
temperature and provides touch sensation. The skin contains several appendages, such as hair 
follicles (HF), sweat glands, and sebaceous glands (SG) [82]. Structurally, the skin consists 
of two layers, the epidermis and the dermis, with an underlying subcutaneous fat layer called 
subcutis (Figure 2) [83,84].  
The subcutis is composed of adipocytes and plays a role in the regulation of HF cycling. The 
connective tissue layer, known as the dermis, is rich in collagen, elastin, and 
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glycosaminoglycans, collectively termed the extracellular matrix (ECM). The dermis 
contains fibroblasts, nerves, lymphatic cells as well as blood vessels and leukocytes. It plays 
an important role in epidermal development, as HF formation is strongly dependent on the 
interaction between dermis and epidermis [82,84]. The dermis is demarcated from the 
overlying epidermis by a basement membrane, which is enriched with ECM proteins and 
growth factors [85,86]. 
 
 
 
Figure 2: Overview of the major 
components of the skin 
The skin consists of two main layers: the 
epidermis, with its associated appendages 
hair follicle and sebaceous gland, and the 
dermis, which is composed of connective 
tissue and contains the blood vessels. 
Underneath resides the subcutaneous fat 
layer.  
 
 
 
1.3.1 The epidermis 
The epidermis is the outermost layer of the skin and encompasses HFs, SGs, and sweat 
glands [85,87,88]. About 95% of the cells within the epidermis are keratinocytes with the rest 
constituted by Langerhans cells, melanocytes, and Merkel cells [83]. Keratinocytes acquired 
their name due to their expression of keratin filaments which make about 85% of a fully 
differentiated keratinocyte [89]. These structural proteins form heterodimers and are 
important for the stability of epithelial cells in the skin [89,90]. Interestingly, keratins are 
found in distinct compartments of the epidermis with typical keratin pairs being associated 
with different developmental stages or locations within the epidermis [90]. 
The epidermis is a stratified epithelium, consisting of four layers that differ in their 
characteristics (Figure 3) [83]. The epidermal stratification program is initiated at around 
E8.5, shorty after gastrulation, and begins with the commitment of ectodermal cells to the 
non-ectodermal lineage [88,91]. Around E16.5-E17.5 the epidermis is fully differentiated 
characterised by the appearance of the cornified layer [82,91].  
The bottom layer, or so-called basal layer, of the stratified epidermis is a single layer of cells 
that are named basal cells. These cells are anchored to the underlying basement membrane 
and are marked by the expression of keratin (K) 5 and K14 [82,83]. Within the epidermis, 
only basal cells have a proliferative potential and are thus responsible for cell division in the 
epidermis [82,85]. Once committed to differentiation, certain basal cells move upward into 
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the spinous layer, where they progressively lose their proliferative capacity. Cells of the 
spinous layer express K1 and K10. The granular layer cells are characterised by dark-staining 
granules, which contribute to grouping of the keratin filaments into tight bundles. This 
culminates in the collapse of the cells, which acquire a flat shape and become the cornified 
layer. During this cornification process, cells of the granular layer express loricrin, which 
constitutes the main structural component of the cornified envelope [92]. Cells of this layer 
seal the epidermis and are continuously shed from the body.  
 
 
Figure 3: Structure of the epidermis 
The epidermis is a stratified epithelium, consisting of four different layers of keratinocytes. Only cells 
within the basal layer harbour a proliferative potential. Upon differentiation, cells migrate upwards into 
the spinous layer and lose their proliferative capacity. Cells in the granular layer start to flatten and 
collapse, eventually forming the cornified layer. Expression of layer-specific markers is indicated. 
 
1.3.2 The hair follicle 
The hair follicle is an appendage from the skin and plays a role in tissue homeostasis and 
repair of injured skin [93]. It arises from the embryonic ectoderm and appears around E14.5. 
Hair follicle formation is controlled by reciprocal signals between the dermis and the 
overlying epidermis [87,94,95]. In response to signals from the dermis, basal cells of the 
epidermis aggregate to form a hair placode. Signals from the placode then stimulate adjacent 
cells to condensate and form the dermal papilla (DP), which in turn instructs the cells of the 
epidermal placode to proliferate and form the hair germ (HG). The HG elongates and 
subsequently differentiates to form the distinct lineages of the mature hair follicle and its hair. 
Wnt/β-catenin and HH signalling have been shown to be crucial for HF morphogenesis, as 
ablation of β-catenin failed to induce the hair placode [96] and HF development was 
abrogated beyond the placode stage in Shh knockout mice [97,98]. 
The mature HF consists of an inner root sheath (IRS) that surrounds the developing hair shaft, 
and an epidermal-derived outer root sheath (ORS), which is a prolongation of the basal layer 
of the interfollicular epidermis (IFE) and expresses K5 and K14 [87,94]. The active growth 
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phase of the HF is called anagen. By postnatal day 16 the HF morphogenesis is completed 
and the lower part of the HF starts to regress (catagen stage). The HF enters its resting stage, 
called telogen. Re-activating signals from the DP initiate another anagen phase, and 
throughout life the HF goes through recurrent phases of growth, regression and rest. 
The telogen HF (Figure 4A) is divided into distinct compartments including isthmus, SG, 
junctional zone, and infundibulum. The lower part of the HF contains the HG and the bulge. 
They are quiescent during telogen but contain cells that are triggered to proliferate upon re-
entering the anagen phase. Leucine-rich repeat containing G-protein-coupled receptor 5 
(Lgr5)-expressing cells (section 1.3.3) are located in this area and are the first HF cells that 
respond to activating signals from the DP [99]. Shh is expressed in the matrix of the 
developing HG and along with Wnt/β-catenin signalling is responsible for anagen induction 
[82]. Furthermore, low levels of Shh were also found in the Lgr5-expressing cells of the HG 
and bulge [99]. Gli1, Gli2, and Gli3 expression was detected in the HG and DP with 
additional expression of Gli2 detected in the basal layer of the bulge-isthmus boarder [100]. 
Gli1 was also detected in the isthmus, and SG show expression of IHH [87,100]. 
 
 
Figure 4: The telogen hair follicle and location of Lgr5-expressing cells 
(A) Different compartments of the hair follicle are indicated. (B) Expression of Lgr5 is found in the 
lower bulge and hair germ.  
 
1.3.3 LGR5 
The leucine-rich repeat containing G-protein-coupled receptor LGR5 has originally been 
discovered as a Wnt target gene in colon cancer, specifically expressed in intestinal crypts 
[101]. Using lineage tracing, Lgr5+ cells were demonstrated to contribute to all lineages of 
the intestinal epithelium, making it the first marker gene for intestinal stem cells at the crypt 
base [102]. Subsequently, Lgr5 has been described as a stem cell marker in various other 
organs such as the stomach [103], mammary glands [104], taste buds [105], kidneys [106] 
and the skin [99]. Lgr5-expressing cells in the skin are located in the lower bulge and hair 
 10 
germ of the telogen HF (Figure 4B) [99]. Transplantation of Lgr5+ keratinocytes onto the 
back of immunocompromised mice revealed their multipotent capacity, as they were able to 
give rise to HFs, SGs, and IFE. During homeostasis, Lgr5+ cells in the hair germ are the first 
cells that start to proliferate in response to signals from the DP. Lineage tracing unveiled that 
the progeny of Lgr5+ cells give rise to all layers of the anagen HF below the SG. 
Remarkably, upon wounding, progeny of Lgr5+ keratinocytes were also able to contribute to 
wound closure and were integrated into the newly formed IFE [107]. Lgr5+ cells in the HF 
were found to express HH pathway components and showed elevated levels of Gli1 and Gli2, 
indicative of active HH signalling [99].  
The biological function of LGR5 has been unveiled using loss-of-function mutants. 
Homozygous deletion of Lgr5 results in neonatal lethality due to ankyloglossia, a craniofacial 
defect where the tongue is attached to the floor of the oral cavity [108]. Additionally, these 
mice showed premature maturation of intestinal cells, indicating that LGR5 might function as 
a negative regulator of Wnt signalling in the developing intestine [109]. However, deletion of 
Lgr5 in the intestine of adult mice did not lead to any apparent phenotype [110]. Regarding 
its involvement in human disease, LGR5 was found be overexpressed in tumours of the liver 
and ovary, most likely due to aberrant activation of the Wnt pathway [111]. Furthermore, up-
regulation of LGR5 was observed in basal cell carcinomas (BCC) of the skin, promoting 
proliferation and tumour formation [112]. 
Recently, R-spondins, previously discovered as secreted Wnt agonists that potentiate Wnt/β-
catenin and Wnt/PCP signalling [113,114], were identified as ligands for LGR5 
[110,115,116]. The exact mechanism of how R-spondin ligands binding to LGR5 enhances 
Wnt signalling is not yet understood. It is speculated that binding of R-spondin to LGR5 
prevents the degradation of the Wnt receptor and its co-receptor by inhibiting the E3 
ubiquitin ligase ZNF3 [117]. Additionally, the R-spondin/LGR5 complex is believed to 
induce phosphorylation of the Wnt co-receptor LRP6, required for downstream signalling 
[115].  
 
1.4 BONE DEVELOPMENT 
The skeleton fulfils several important functions such as protection of inner organs from 
injury, production of blood cells and furthermore provides a framework for attachment of 
muscles and other tissues enabling body movement. The bones of the skeleton originate from 
three distinct embryonic lineages [118]. The somites, which derive from strips of mesoderm 
located on either side of the neural tube, generate the vertebrae and the ribs [118,119]. The 
limb skeleton arises from the lateral plate mesoderm and many of the skull bones originate 
from ectodermal-derived cranial neural crest cells. There are two different ways of how bone 
is formed: endochondral and intramembranous ossification [91,118]. More than 95% of the 
skeleton is modelled through the former process, whereas numerous craniofacial bones are 
formed through intramembranous ossification. 
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Both endochondral and intramembranous ossification begin with migration of mesenchymal 
cells from the mesodermal or ectodermal lineages to the site of the future bones [118,120]. 
They then form condensates of high cellular density and in the intramembranous ossification 
process, directly differentiate into bone-forming osteoblasts. Osteoblasts synthesise and 
secrete a collagen-proteoglycan matrix that can bind calcium salts, ultimately resulting in 
calcification [118].  
 
 
Figure 5: Endochondral bone formation 
Endochondral bone formation is initiated by the formation of mesenchymal condensates, followed by 
proliferation and differentiation into chondrocytes. Chondrocytes continue to proliferate, thereby 
promoting bone growth. Cells in the centre of the growing bone stop dividing and become first pre-
hypertrophic and then hypertrophic. The primary ossification centre is established and vascularisation 
takes place. Further bone growth results in the formation of secondary ossification centres at each 
end of the bone. 
 
In contrast to intramembranous ossification, endochondral bone formation (Figure 5) is a 
multistep process and involves a cartilage intermediate [91,118,121,122]. After formation of 
mesenchymal condensations, cells located in the core of the condensations differentiate into 
cartilage cells. These so-called chondrocytes undergo rapid proliferation, driving the linear 
growth of the skeletal element, producing cartilage-specific extracellular matrix (ECM) rich 
in type II collagen and the proteoglycan aggrecan. Cells in the centre stop dividing and 
undergo differentiation, increasing their volume, becoming first pre-hypertrophic and then 
hypertrophic. Cells flanking the hypertrophic zone then differentiate into osteoblasts and 
invade the mineralised cartilage matrix together with blood vessels and establish the primary 
ossification centre. Hypertrophic chondrocytes undergo apoptosis and the cartilage matrix 
slowly becomes replaced by a calcified bone matrix produced by osteoblasts. As 
differentiation and subsequent calcification occurs in the core, proliferating chondrocytes 
become restricted to each end of the growing bone [122]. Secondary ossification centres form 
upon further growth of the bone, and in long bones of the limb proliferation of chondrocytes 
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situated between the two ossification centres proceeds. The cartilage here is called “growth 
plate” and cells at the top constitute resting chondrocytes, which probably serve as precursors 
to the proliferating chondrocytes. 
HH signalling is a key regulator in skeletal morphogenesis controlling chondrocyte and 
osteoblast differentiation [123,124]. IHH is produced by pre-hypertrophic and hypertrophic 
chondrocytes, stimulating chondrocyte proliferation [91,121,125]. Additionally, IHH is 
important for initiation of osteoblast differentiation from the cells flanking the hypertrophic 
zone. Apart from its role in endochondral bone formation, HH signalling also plays an 
important role in intramembranous ossification [124]. 
 
1.4.1 Limb formation 
Limbs develop from small buds of mesenchymal cells, which are covered by surface 
ectoderm [119]. Fore- and hindlimb buds arise at around E9 - E9.5 and E9.5 - E10, 
respectively. An early event in limb formation is the appearance of the apical ectodermal 
ridge (AER), a specialised epithelium required for proximal-distal (P-D) outgrowth of the 
limb, at the tip of the limb bud [126]. At E11.5, the fore- and hindlimb buds flatten and by 
E13.5 individual digits can be identified [119]. Digit patterning along the anterior-posterior 
(A-P) axis (thumb to little finger) requires a region at the posterior limb bud mesoderm called 
zone of polarising activity (ZPA). A positive feedback loop is established between the two 
signalling centres, AER and ZPA, regulating limb development [127]. Limb formation and 
digit patterning is strongly dependent on HH signalling and SHH is expressed in the ZPA 
from E9.5 onwards (Figure 6) [128]. SHH produced from the ZPA establishes a P-A 
gradient and counteracts the activity of GLI3R. However, it appears that SHH is only 
required very early and transiently for digit patterning [128]. The ratio of GLI3FL and GLI3R 
across the A-P axis is believed to be responsible for digit patterning and prior to SHH 
expression, GLI3 has a crucial role in the pre-patterning required for establishment of the A-P 
axis [127,129,130].  
 
Figure 6: Limb formation 
Limb buds arise around E9.5 in embryonic development. 
At the distal end the apical ectodermal ridge (AER) 
forms, which is required for proximal-distal outgrowth of 
the limb. The zone of polarising activity (ZPA) is 
established at the posterior region. SHH expression from 
the ZPA counteracts GLI3 in the anterior end of the 
growing limb bud, and the ratio of GLI3FL and GLI3R 
across the anterior-posterior axis is crucial for patterning 
of the limb. 
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1.5 HH SIGNALLING IN DEVELOPMENT AND DISEASE 
Owing to its crucial role in numerous developmental processes, it is not surprising that 
deregulation of the HH pathway is associated with severe congenital malformations. 
Insufficient signalling due to inactivating mutations in the SHH gene is believed to be the 
main cause of holoprosencephaly (HPE) [131-133]. HPE is a common brain malformation, 
resulting from incomplete cleavage of the forebrain during early embryonic development 
[133]. It is characterised by facial anomalies with a wide phenotypic spectrum, ranging from 
anophthalmia and cyclopia in the most drastic cases to cleft lip and hypotelorism in the 
milder forms of HPE. Besides SHH, mutations in the PTCH1 gene probably affecting SHH 
binding, have been identified in patients with HPE [134]. 
Gorlin syndrome, also known as nevoid basal cell carcinoma syndrome, is tightly linked with 
aberrant HH signalling. It is an autosomal dominant disorder, mainly caused by loss-of-
function mutations in PTCH1 [135,136]. Gorlin syndrome is a condition that affects many 
areas of the body and is primarily characterised by a predisposition to develop an inordinate 
number of BCC of the skin [137]. In addition, affected people show a high incidence of other 
tumour types such as medulloblastoma, meningioma, and rhabdomyosarcoma. Gorlin 
syndrome patients are furthermore afflicted with developmental malformations, including 
spina bifida, skeletal abnormalities such as bifid ribs, palmar/plantar pits, cleft lip and/or 
palate, and jaw keratocysts. Although Gorlin syndrome is predominantly caused by PTCH1 
haploinsufficiency, mutations in SUFU have been reported [138,139].  
Both Greig cephalopolysyndactyly (GCPS) and Pallister-Hall syndrome (PHS) are caused by 
mutations in the GLI3 gene [140]. GCPS is characterised by polydactyly and craniofacial 
anomalies, including macrocephaly and hypertelorism. It is associated with various GLI3 
mutations such as deletions, insertions, as well as nonsense, missense, and frameshift 
mutations, resulting in the disruption of one GLI3 allele. PHS affects many parts of the body 
and affected people exhibit hypothalamic hamartoma, pulmonary segmentation defects, 
polydactyly, and syndactyly.  Mutations causing PHS are predominantly found in the central 
part of the gene and lead to the production of a truncated GLI3 protein that can only function 
as a repressor.  
Mutations in IHH have been associated with brachydactyly, an anomaly defined by shortened 
phalanges or metacarpals [141], and acrocapitofemoral dysplasia, characterised by short 
limbs, brachydactyly, and a narrow thorax [142].  
While deregulation of the HH signalling pathway during embryo development results in 
congenital defects, aberrant activation in adults is found in a variety of cancers including 
medulloblastoma and BCC [5]. BCCs arise from keratinocytes and are predominantly found 
on sun-exposed areas of the skin [143]. Despite being the most common type of cancer 
amongst the Caucasian population, BCCs are not associated with high mortality rates since 
they rarely metastasise. Nevertheless, they can invade and destroy local tissue. While Gorlin 
syndrome predisposes to the development of BCC, the vast majority of BCCs occur 
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sporadically. Although mainly caused by PTCH1 inactivating mutations, less frequently SMO 
and SUFU mutations have been reported in sporadic BCCs [144]. Mutations in SUFU are 
also observed in meningioma [145], multiple hereditary infundibulocystic BCC [146], 
medulloblastoma [147], and merkel cell carcinoma [148].  
Since over-activation of the HH pathway is most often due to loss-of-function mutations in 
Ptch1, inhibiting downstream signalling by targeting SMO has become an attractive 
therapeutic strategy. In 2012, vismodegib became the first SMO inhibitor approved by the US 
Food and Drug Administration (FDA) for treatment of locally advanced or metastatic BCC 
[149,150]. In July 2015, this was followed by approval of sonidegib for locally advanced 
BCC [150,151]. Despite the major progress in treatment of BCCs, challenges remain as 
tumours may develop resistance to these inhibitors, mostly due to mutations in the SMO 
receptor [152]. Hence, restraining HH signalling downstream of SMO is desirable [153] and 
pre-clinical studies targeting GLI transcription factors are ongoing [154]. 
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2 TOOLKIT FOR STUDYING DEVELOPMENT AND 
DISEASE 
 
2.1 MOUSE EMBRYONIC STEM CELLS, EMBRYOID BODIES, AND 
TERATOMAS 
In Paper I, Sufu-/- mouse embryonic stem cells (mESCs) were derived, characterised, and 
utilised to study the role of SUFU in lineage differentiation processes. This section provides a 
brief summary on mESC history, characteristics, and their use in developmental biology 
research. 
mESCs originate from the ICM of the E3.5 pre-implantation blastocyst (section 1.2 and 
Figure 7A) and were isolated for the first time in 1981 [73,74]. ESCs are characterized by 
their ability to self-renew indefinitely and by their pluripotency, that is, the potential to 
contribute to all tissues and cellular lineages (Figure 7B) [155,156]. The transcription factors 
SOX2, NANOG and OCT4 are key to governing the molecular mechanisms that maintain 
self-renewal and repress differentiation [155]. Soon after their first derivation, mESCs were 
shown to be able to form germ-line chimaeras [157], meaning that mESCs injected into 
genetically different host blastocysts participated in the development of the embryo, 
contributing to various tissues including mature gametes, i.e. egg or sperm. As mESCs can 
easily be manipulated genetically, they have emerged as an essential tool for investigating 
gene function in development and disease [158]. Insertion of transgenes into mESCs or gene 
targeting through homologous recombination [159,160] followed by injection into 
blastocysts allows the analysis of the effects of genetic changes in vivo. In addition to their 
importance for manipulating the mouse embryo, mESCs are used in vitro for studying 
pluripotency, self-renewal, lineage choice, and differentiation, thereby increasing our 
understanding on regulatory networks affecting stem cell maintenance and cell specification 
processes.  
Traditionally, mESCs are cultured on a feeder layer of mitotically inactivated mouse 
embryonic fibroblasts (MEF) and require the presence of the cytokine leukaemia inhibitory 
factor (LIF) to retain their undifferentiated state [156]. Withdrawal of LIF induces 
differentiation and when combined with culturing ES cells in high density, non-adherent, 
suspension culture leads to the formation of embryoid bodies (EB) [158,161,162]. EBs 
represent 3D cell aggregates, which recapitulate early embryonic development. Although 
they show less structural organisation than the actual embryo, the time course of gene 
expression mimics embryonic development. EB formation starts with the aggregation of 
ESCs, followed by the formation of primitive endoderm as an outer layer of the EB, and the 
emerging of derivatives of the three germ layers mesoderm, endoderm, and ectoderm inside 
the structure. As differentiation occurs spontaneously, without addition of external factors, 
EB formation is commonly used to assess the pluripotent capacity of ESCs. Apart from that, 
EBs frequently constitute the initial step in guided differentiation protocols where 
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specialisation towards a certain cell type is accomplished through adding specific factors to 
the cell culture medium. 
 
 
Figure 7: Origin and use of embryonic stem cells 
(A) The one-cell embryo, called zygote, undergoes several rounds of cleavage before reaching the 
blastocyst stage at E3.5. Blastocysts contain the inner cell mass (ICM), which eventually give rise to 
the embryo. (B) Mouse embryonic stem cells (mESC) originate from the ICM of the E3.5 blastocyst. 
Due to their pluripotent capacity, mESCs can be differentiated towards cells of the three germ layers, 
ectoderm, endoderm and mesoderm. Examples of germ layer-derivatives are stated. 
 
Similar to the EB assay in vitro, in vivo teratoma formation is used to monitor the pluripotent 
capacity of ESCs [163]. Teratomas comprise a group of largely benign tumours composed of 
derivatives of the three germ layers and usually arise in the ovary or testis [164]. For the 
purpose of evaluating the differentiation potential of ESCs, teratomas can be experimentally 
induced in mice by transplanting ESCs into immunocompromised hosts [163]. In this in vivo 
environment, ESCs are exposed to a compilation of growth factors and extracellular matrix 
proteins, which is difficult to mimic in a cell culture dish. This mixture of factors promotes 
ESC proliferation and their development into a tumour. Similar to EBs, teratomas are 
haphazardly organized, but contain structures that resemble normal tissue such as cartilage, 
gland-like structures, and neural rosettes.  
Much of our knowledge on regulation of pluripotency, stem cell maintenance, and cell 
differentiation is rooted in mESC research. The increased use of human ESC (huESC) and 
induced pluripotent stem cells (iPSC), which are generated from already differentiated cells 
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[165], may however outcompete the need for mESCs in these areas. Additionally, the 
emergence of new gene editing techniques such as CRISPR-Cas9 and TALENs, which allow 
relatively easy gene manipulation in huESCs and iPSCs at high efficiency, enables 
investigating gene function and disease modelling in these cell systems in vitro [166]. Despite 
the strong competition in in vitro research, mESCs will however continue to be an essential 
tool in developmental biology, used to deepen our knowledge in early embryogenesis, 
particularly since research on early human embryonic development is limited due to ethical 
and legal constraints [167]. 
 
2.2 MOUSE MODELS 
Sufu knockout (Sufu-/-) blastocysts were the source of ESCs used in Paper I and Sufu-/- E9.5 
embryos were used in Paper II. Sufu knockout mice represent an example of a conventional 
gene knockout, where the gene of interest is inactivated to unveil its role in vivo. The ground-
breaking work of Capecchi, Evans, and Smithies, namely the isolation of mESCs and the 
discovery of homologous recombination [159,160,168], led to the generation of the first 
knockout mice in 1989 [169-172]. Inactivation of the gene of interest is accomplished by 
either disrupting its open reading frame to block its expression, or by deleting exons critical 
for gene function. Conventional gene knockouts provide a relatively fast way of obtaining 
information on the biological role of a gene in embryogenesis and physiological homeostasis. 
However, such knockouts can be embryonically lethal if the targeted gene is essential for 
development, as in the case of Sufu [36], impeding investigations of gene function beyond a 
certain embryonic stage.  
To overcome this problem, conditional knockout mice based on the CRE/loxP system, such 
as the SufuFL/FL mouse used in the preliminary study, have been developed. Using this 
technology, any DNA region that is flanked by loxP sites (“floxed”) can be excised and, in 
the case of conditional knockout mice, leads to the disruption of the gene (Figure 8A). The 
loxP site is a 34-bp nucleotide sequence that serves as recognition site for the CRE 
recombinase, an enzyme derived from the P1 bacteriophage, which cuts and mediates 
recombination between two loxP sites, excising DNA located between them [173]. 
Expression of Cre can be driven by a specific promoter, thus enabling tissue-specific deletion 
of the desired DNA sequence.  
In addition to spatial excision of the floxed DNA region, temporal control is achieved by 
using inducible CRE enzymes as used in the preliminary study. Here, we made use of the 
Lgr5-EGFP-IRES-CreERT2 knock-in mice [102], from now on referred to as Lgr5Cre mice, 
where the sequence for the enhanced green fluorescent protein (eGFP) was placed behind the 
Lgr5 promoter, enabling identification of Lgr5-expressing cells by eGFP fluorescence. 
Furthermore, an internal ribosomal entry site (IRES) is in place, followed by a sequence 
encoding for the CreERT2 fusion protein, which consists of the CRE recombinase and a 
modified ligand-binding domain of the oestrogen receptor. Usually located in the cytoplasm, 
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administration of the synthetic oestrogen analogue tamoxifen enables nuclear entry of the 
CreERT2 protein, leading to CRE-mediated loxP-flanked DNA sequence excision [174].  
As the CRE recombinase excises any DNA sequence placed between loxP sites, it cannot 
only be used for permanent gene inactivation, but also for enabling reporter gene expression 
for lineage tracing purposes. In this system, a conditional reporter gene is present in the 
mouse genome, typically inserted into the ubiquitously expressed Rosa26 (R26) locus [175], 
containing a loxP-flanked stop sequence in front of the protein-coding region. Various 
reporter genes exist, of which the red fluorescent protein tdTomato (Tomato) [176] was 
employed in the preliminary study. As CRE-mediated recombination of the loxP sites is 
irreversible, targeted cells as well as their progeny will be permanently marked by the 
reporter gene expression (Figure 8B). 
 
 
Figure 8: The CRE-loxP system and lineage tracing 
(A) DNA (e.g. exon 1) is located between two loxP sites, which are recognised by the CRE 
recombinase. CRE mediates the excision of the DNA region flanked by loxP sites, and after re-ligation 
one loxP site is retained. (B) In Lgr5Cre;Tomato;SufuFL/FL mice, cells with an active Lgr5 promoter 
express eGFP and the CreERT2 recombinase. Usually located in the cytoplasm, the CreERT2 enters 
the nucleus when bound by tamoxifen and subsequently mediates excision of loxP flanked DNA 
sequences. As a consequence, the stop codon in front of the tomato reporter gene is removed, 
permanently marking the cell and all of its progeny red. Additionally, exons 4-8 of the Sufu gene are 
removed, leading to its inactivation. 
 
Conditional gene knockouts in combination with reporter gene expression, as applied in the 
preliminary study, hence allow tissue-specific inactivation of the gene of interest, 
simultaneously labelling the targeted cells. Utilising conditional knockout mice has made it 
possible to decipher the biological function of genes in various tissues, yet it only permits an 
all-or-nothing approach.  
  19 
Hypomorphic mice, such as the Sufu hypomorphic mouse studied in Paper II, allow 
investigating consequences of reduced protein function in a global manner [177]. In 
hypomorphic mice, expression or activity of a protein is higher than in knockout mice, yet 
significantly lower compared to wild-type alleles. Thus they can be used to gain insight into 
tissue-specific sensitivity towards reductions in protein levels or activity. Additionally, by 
crossing hypomorphic with knockout mice, offspring with further reduced protein expression 
levels can be obtained. This enables to decipher the degree of protein reduction or activity 
required for evoking a phenotype. 
In Paper III, we employed the tetracycline (tet)-controlled, inducible gene expression system 
[178] to examine the effects of human LGR5 (huLGR5) expression on skin development and 
homeostasis. This system is based on the bacterial tet operon and permits reversible control of 
gene expression, regulated by the presence or absence of tet or its derivative doxycycline. To 
specifically express a gene of interest, the promoter is replaced by a tet-response element 
(TRE). In the tet-off system (Figure 9), which we primarily used in Paper III, cells need to 
additionally express the tetracycline-controlled transactivator (tTA). The tTA is a fusion 
protein of the C-terminal domain of the tetracycline repressor (tetR) and the herpes simplex 
virus transcription activator domain. In the absence of doxycycline, the tetR portion of the 
tTA protein will recognize and bind to the TRE sequence, and the activation domain initiates 
gene transcription by recruiting RNA polymerase II. Contrary, when doxycycline is present, 
tTA will bind the tet derivative instead, thus abrogating target gene expression. In Paper III, 
we used a mouse line with the tTA expression under the control of the keratin 5 (K5) 
promoter [179] to regulate expression of huLGR5 (TRE-LGR5) in the skin. 
 
Figure 9: The Tet-OFF system 
(A) The expression of the tetracycline-controlled transactivator (tTA) is under the control of a tissue-
specific promoter. (B) In the absence of the tetracycline derivative doxycycline, the tTA protein will 
bind to the tet-response element (TRE), which is placed in front of the gene of interest, and initiate 
gene transcription. In the presence of doxycycline no transcription of the target gene occurs, as tTA 
binds to the tetracycline derivative instead. 
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Using animal models provides certain advantages for addressing biological research 
questions, mainly as the cells of interest are kept within their natural environment, surrounded 
by factors influencing their behaviour. This is contrast to in vitro cell culture models, where 
cells are kept in an artificial environment, possibly changing their characteristics. Yet there 
are certain drawbacks accompanying in vivo models. Tamoxifen or doxycycline may cause 
unwanted side effects disturbing homeostasis or affecting experimental outcome [180,181]. 
Moreover, ethical aspects have to be considered when using mouse models in research, with 
the general aim to reduce the number of animals for experimental purposes and to alleviate or 
minimise their potential pain, suffering or distress. 
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3 AIMS 
 
The general aim of this thesis was to investigate the function of SUFU and LGR5 during 
mouse embryogenesis, tissue differentiation, and tumour formation. 
Specific aims: 
Paper I  Characterise Sufu-/- ESCs and explore the biological significance 
  of SUFU in lineage differentiation processes  
Paper II  Investigate the effects of globally reduced SUFU levels on 
  embryo development in a Sufu hypomorphic mouse model  
Paper III  Examine the consequences of increased huLGR5 expression on 
  skin development and homeostasis  
Preliminary Study Study the potential of SUFU-deficient Lgr5+ HF stem cells to 
  initiate tumour formation in skin 
 
 
 

  23 
4 RESULTS 
 
4.1 PAPER I 
Suppressor of Fused Plays an Important Role in Regulating Mesodermal 
Differentiation of Murine Embryonic Stem Cells In Vivo  
Mammalian SUFU has been demonstrated to function as an inhibitor of HH signalling and 
is essential for embryonic development [36,37]. In this study we sought to delineate the role 
of SUFU in lineage differentiation during early embryogenesis. We derived and 
characterised mESCs from the ICM of Sufu-/- and wild-type E3.5 pre-implantation 
blastocysts and investigated the differentiation capacity of Sufu-/- mESCs in vitro and in 
vivo. 
We showed that Sufu-/- mESCs expressed the pluripotency markers alkaline phosphatase, 
SSEA-1, Nanog, Sox2, and Oct4 indicating their undifferentiated state. Additionally, like 
their wild-type counterparts, Sufu-/- mESCs exhibited normal mESC morphology, such that 
they formed dense, separated colonies with tight borders. Using qRT-PCR we demonstrated 
that Sufu-/- mESCs similar to wild-type mESCs expressed Shh, Ihh, Dhh, Smo, Gli2, and 
Gli3. Our analysis further revealed that Sufu-/- mESCs show increased pathway activation, 
but not to the same extent as observed in Sufu-/- MEFs. Thus indicating potential presence 
of additional factors impeding HH signalling in mESCs or the absence of an external 
stimulus appearing upon differentiation. 
To explore the in vitro differentiation capacity of Sufu-/- mESCs we utilised the EB 
formation assay described in section 2.1. During spontaneous differentiation in vitro, cells 
lacking Sufu showed a strong increase in HH signalling activation, as measured by Gli1 and 
Ptch1 mRNA expression. Remarkably, with increasing culture duration, EBs derived from 
Sufu-/- mESCs appeared significantly smaller in size, reflected also in the diminished 
production of ATP. Moreover, loss of Sufu did not impair the capacity of mESCs to 
differentiate towards mesoderm and endoderm in vitro, whereas the neuroectodermal 
marker expression was decreased.  
As we observed a diminished neuroectodermal differentiation, we further sought to explore 
the pluripotent potential of our mESCs in an in vivo setting. For that purpose, Sufu-/- and 
wild-type mESCs were injected subcutaneously into immunocompromised mice to form 
teratomas (section 2.1), which developed at a similar frequency and growth rate. Despite 
lower neural marker expression in Sufu-/- EBs in vitro, teratomas of both genotypes were 
dominated by neuroectodermal derivatives. We also detected endodermal components in 
the teratomas irrespective of genotype. Intriguingly, although some mesodermal derivatives 
were identified, Sufu-/- mESCs failed to form cartilage and bone, thus pointing to a role for 
HH signalling and in particular SUFU in mesodermal lineage differentiation processes.  
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Given the lack of cartilage and bone in Sufu-deficient teratomas, we subjected our mESCs 
to a chondrocyte and osteocyte differentiation protocol in vitro to investigate the 
requirement for Sufu during directed differentiation. In contrast to our teratoma data, Sufu-/- 
mESCs were able to form osteocytes and chondrocytes, indicating that additional 
exogenous factors present in the culture media may compensate for the absence of Sufu. 
In conclusion, we showed that Sufu loss does not induce spontaneous differentiation of 
mESC or alter the expression of pluripotency markers. However, upon differentiation both 
in vitro and in vivo Sufu-/- mESCs demonstrated a limited capacity to contribute to all germ 
layer derivatives, suggesting a role for Sufu in the lineage specification processes.  
 
4.2 PAPER II 
Differential requirement for SUFU in tissue development discovered in a 
hypomorphic mouse model 
As mice lacking Sufu die in utero around E9.5, we initially aimed to generate a conditional 
Sufu knockout allele allowing spatio-temporal control of Sufu expression. However, we did 
not obtain viable homozygous offspring for the targeted allele. Excluding the possibility of 
embryonic lethality at E9.5, we reasoned that we rather had obtained a hypomorphic allele 
(Sufuhypo/hypo; section 2.2). This opened up new and exciting possibilities to, instead of 
limiting studies on Sufu to tissue-specific questions, investigate the effects of altered SUFU 
function/activity on embryogenesis and organ development in a global manner. 
We showed that Sufuhypo/hypo embryos are viable up to E18.5, but exhibit severe 
developmental defects including polydactyly in fore- and hindlimbs, cleft lip and palate, 
exencephaly, and omphalocele. Analysis at the molecular level revealed a drastic reduction 
of Sufu wild-type mRNA in E9.5 embryos. SUFU full-length protein was reduced to 
approximately a fifth of wild-type levels but did not lead to increased target gene 
expression. However, GLI1, GLI2, as well as GLI3FL and GLI3R proteins were reduced, 
corroborating SUFU's role in the stabilisation of these proteins.  
Since HH signalling has a pivotal role in bone development [125] and Sufuhypo/hypo embryos 
displayed limb anomalies, we analysed effects of reduced SUFU levels on the skeletal 
system at E16.5 and E18.5. Using alcian blue/alizarin red staining we showed that 
Sufuhypo/hypo embryos exhibited a magnitude of malformations affecting a diverse range of 
skeletal structures. Skull anatomy in Sufuhypo/hypo was severely altered, manifesting by 
reduced bone density, absence of various bone structures, clefting of the nasal region and 
the frontal bone, as well as truncated mandibles. Furthermore, ossification of long bones as 
well as autopods was impaired. However, we did not detect significant changes in target 
gene expression in E16.5 Sufuhypo/hypo front- and hindpaws compared to control. Additional 
skeletal malformations included distorted and branching ribs, as well as split sternum and 
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diminished ossification of the pubic bone. Taken together, our data indicate that certain 
levels of SUFU are required to ensure proper bone development.   
In order to assess the effects of reduced SUFU levels on skin development we analysed skin 
of E18.5 Sufuhypo/hypo embryos histologically. Using immunohistochemistry to identify the 
various layers of the interfollicular epidermis, we could not detect disturbances or 
anomalies in the stratification of Sufuhypo/hypo skin. Additionally, the number of HFs was 
comparable to controls. Furthermore, skin barrier development and function was normal in 
Sufuhypo/hypo embryos. Expression of the HH target genes Ptch1 and Hhip was unchanged in 
the E16.5 Sufuhypo/hypo skin, whereas Gli1 mRNA was reduced. To evaluate long-term 
effects of strongly diminished SUFU levels on skin homeostasis we performed skin 
transplantation studies where skin of E18.5 Sufuhypo/hypo and control embryos was engrafted 
onto immunocompromised mice and analysed after 14 weeks. Greatly reduced SUFU levels 
did not compromise hair growth and did not result in hyperplasia or defects in epidermal 
stratification, indicating that the low levels of SUFU present are sufficient to maintain 
development and function in embryonic and transplanted skin.  
During our studies we have established that embryos homozygous for the Sufu 
hypomorphic allele die perinatally but Sufuhypo/+ mice develop normally without any 
obvious phenotype. As previous findings in our lab had shown that mice heterozygous for 
Sufu (Sufu-/+) develop a skin phenotype as they age [36], we examined the skin of aged 24-
months old Sufuhypo/+ mice. We detected some hyperplastic areas as well as basaloid 
follicular hamartomas in the ventral skin, yet smaller in size and at a lower frequency than 
in Sufu-/+ control animals, consistent with graded SUFU levels.  
In addition to skin and bone, we examined the lungs of Sufuhypo/hypo embryos at various 
stages of development. No differences between control and Sufuhypo/hypo were apparent at 
E13.5 and E15.5. However, lungs with low SUFU level displayed severe defects in alveolar 
development at E18.5 with significantly reduced alveolar space in favour of lung tissue. 
Similar to skin, we could not detect significant changes in Ptch1 and Hhip mRNA levels in 
E16.5 Sufuhypo/hypo lungs, while Gli1 expression was downregulated.  
In summary, this study explored the effects of significantly reduced SUFU levels on 
embryogenesis. We demonstrated that tissues require different levels of SUFU for normal 
development and provide novel insights into SUFU's role during organogenesis. In 
addition, we provide a new tool to further dissect the molecular and biological functions of 
SUFU.  
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4.3 PAPER III 
A conditional transgenic mouse line for targeted expression of the stem cell 
marker LGR5  
LGR5, a co-receptor for Wnt signalling, has been identified as a marker of adult stem cell 
populations in multiple tissues including the hair follicle [99], mammary gland [104], 
intestines, and the stomach [102]. In addition, it is found to be upregulated in BCCs [112]. 
To elucidate the effects of increased LGR5 expression on skin development and 
homeostasis, we generated a mouse line where expression of human LGR5 (huLGR5) is 
under the control of a tetracyline-responsive promoter element (TRE-LGR5).  
To achieve expression of huLGR5 in skin during embryogenesis, TRE-LGR5 mice were 
crossed with K5tTA transgenic mice in the absence of doxycycline (section 2.2). HuLGR5 
was detected in the HFs, the IFE, and the sebaceous glands. However, we observed a more 
uneven expression pattern in the adult compared to the embryonic IFE. The consequences 
of huLGR5 expression in K5+ cells during development were examined at the embryonic 
and adult stages and revealed macroscopic and microscopic changes, including sparse fur 
coat, abnormal sebaceous gland maturation and hyperplasia of the interfollicular epidermis. 
However, no tumour formation was observed. 
K5tTA;LGR5 double heterozygous mice were smaller, had less dense fur, and showed a 
significant reduction in body mass, independent of gender. We investigated whether a 
defective skin barrier could explain the decreased body weight, however, no differences in 
skin barrier formation during embryo development were found. In adults, transepidermal 
water loss indicated that male, but not female barrier function was disturbed. Double 
transgenic mice exhibited a kink tail throughout their lifespan yet no skeletal malformations 
were detected at E18.5. Thus excluding skeletal deformations during embryogenesis as the 
underlying cause of the kink tail phenotype.  
Microscopic analysis of dorsal skin biopsies of the K5tTA;LGR5 adult mice revealed an 
increased degradation of sebocytes, hyperplasia of the interfollicular epidermis and the 
basal keratinocyte layer around the bulge and the infundibulum. Additionally, the IFE of 
double transgenic mice displayed an increased number of Ki67+ cells and ectopic 
expression of K6, whereas expression of K5, K14, and K10 were similar to controls. 
Further investigations unveiled that the expression of Wnt5a, an inducer of non-canonical 
Wnt signalling, was upregulated. Moreover, we found increased levels of the LGR5 ligands 
R-spondins, as well as the HH pathway-associated transcription factor Gli1. 
Intriguingly, discontinuing huLGR5 expression at P21 reverted the skin-associated 
phenotypes when analysed at the age of 16 weeks. While the induction of huLGR5 at P21 
did not lead to morphological changes in K5tTA;LGR5 animals throughout their lifetime.  
Taken together, these data demonstrate that initiation of huLGR5 expression in K5+ cells 
during embryogenesis but not in young adult mice alters skin development and 
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homeostasis. Additionally, we have created a new model to further dissect the role of LGR5 
in development, homeostasis, and cancer. 
 
4.4 PRELIMINARY STUDY 
Conditional inactivation of Sufu in Lgr5+ HF stem cells is not sufficient to 
induce tumour formation 
We previously reported that Sufu heterozygous mice developed a skin phenotype as they 
aged, including epidermal basaloid proliferations [36] and Paper II). Furthermore, loss of 
Sufu in basal cells of the skin was shown to lead to compromised epidermal stratification, 
hyperplasia, and epithelial invaginations [30]. Lgr5 is a known stem cell marker of the HF 
[99] and has shown tumour initiation capacities, as inactivation of Ptch1 in Lgr5 expressing 
cells (Lgr5Cre;Ptch1FL/FL) caused development of BCC-like lesions in the HF compartment 
[107]. Thus, we aimed to analyse mice with conditional homozygous inactivation of Sufu in 
the Lgr5+ HF stem cells.  
To explore the tumour-initiating capacities of Lgr5+ Sufu-deficient HF stem cells, we 
generated Lgr5Cre;Tomato;SufuFL/FL mice. In this model, the expression of Sufu is abrogated 
upon CRE recombination (section 2.2), and simultaneously tomato expression is induced, 
labelling Lgr5-expressing cells red. Additionally, the identification of Lgr5-expressing cells 
was achieved by the expression of enhanced green fluorescent protein (eGFP) driven by the 
Lgr5 promoter. Deletion of the Sufu allele in Lgr5+ cells was done by intraperitoneal 
tamoxifen injection at postnatal week 3 (P3w) or postnatal week 8 (P8w). Dorsal skin 
biopsies of 3-5 mm in diameter, resulting in full-thickness wounds, were taken at different 
time-points. When injected at P3w, biopsies were taken 8 and 21 days after tamoxifen 
treatment (biopsy 1 and biopsy 2, respectively). Biopsies from mice receiving tamoxifen at 
P8w were taken 10 days and 5 weeks after treatment (biopsy 1 and biopsy 2, respectively).  
Histological analysis of biopsies 1 and 2 did not reveal any changes in the HFs, 
independent of the time-point of induction. We detected labelled cells in the lower bulge 
and HG of tamoxifen treated mice (Figure 10A and A'), whereas absence of either CRE or 
tamoxifen did not, or only at a very low frequency, lead to recombination (Figure 10B and 
B'). Hence, we concluded that the chosen time-points may have been too early to observe 
clear phenotypic changes caused by Sufu inactivation. However, we still did not detect 
alterations in the third skin biopsy of the first P8w experiments, taken 10 weeks after 
tamoxifen injection. Thus, in order to evaluate long-term effects of Sufu deletion in Lgr5+ 
cells, the third skin biopsy of the remaining P3w and P8w experiments were postponed to 
approximately 1 year after tamoxifen injection. However, despite this late time-point, we 
neither detected macroscopic nor microscopic changes in the HFs. Finally, mice were 
sacrificed 60-80 weeks post-tamoxifen treatment and skin of various regions (dorsal, 
wound, ventral, ear, paw, and tail) was collected and analysed, but also here we did not 
observe any signs of hyperplasia or HF-associated BCC-like lesions. 
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Upon wounding, Lgr5Cre;Ptch1FL/FL mice, in addition to HF-associated BCC-like lesions, 
developed basaloid proliferations in the IFE [107]. However, we did not detect changes in 
the newly formed wound epidermis of Lgr5Cre;Tomato;SufuFL/FL mice. 
Thus, we concluded that deletion of Sufu in Lgr5-expressing cells does not suffice to induce 
tumour formation, which furthermore could not be triggered by wounding.  
 
Figure 10: Labelling of Lgr5Cre;Tomato;SufuFL/FL hair follicle stem cells 
(A) Confocal microscopy image of the first biopsy of tamoxifen-treated Lgr5Cre;Tomato;SufuFL/FL mice, 
revealing expression of the red fluorescent protein in the lower bulge and hair germ of the hair follicle 
(HF). (A') Magnification of a tomato-labelled HF. (B) Red cells are detected very rarely in HFs of 
Lgr5Cre;Tomato;SufuFL/FL without tamoxifen treatment. Confocal image of the second biopsy is 
shown. (B') Magnification of a HF with a singular recombination event. 
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5 DISCUSSION AND FUTURE PERSPECTIVE 
 
In Paper I, we established Sufu-/- ESC lines and showed that Sufu is important during early 
embryonic differentiation processes. The results of the study elicited some interesting 
hypothesis-generating questions. The decrease in EB size was unexpected, as HH signalling 
is known for its pro-proliferative role [2] whereas compromised HH signalling resulted in 
reduced EB size [182]. Staining for the proliferation marker phospho-histone H3 and 
cleaved caspase 3 for identifying apoptotic cells did not unravel the mechanism behind the 
observed decrease in EB size, since the number of proliferative cells per EB was 
comparable and more apoptosis was detected in the wild-type EBs. One possibility could be 
a decrease in cell size, although no reports so far have linked HH signalling to that.  
With regards to early embryonic development, in vitro differentiation yielded chondrocytes 
and osteoblasts despite their absence in teratomas, leaving open the precise role of Sufu in 
lineage differentiation. Directed in vitro differentiation implies the addition of external 
factors in concentrations that are possibly different from those naturally occurring in 
embryonic development in utero. Due to these exogenous differentiation factors, the 
crosstalk between cells and their microenvironment may be disturbed. Consequently, fine-
tuning processes ensuring proper cell specification may be masked and in our case the 
requirement for Sufu in cartilage and bone development within this context is overruled. To 
provide more insight onto this question, a chimeric mouse may be required by injecting 
labelled Sufu-/- mESCs into blastocysts, where the contribution of Sufu-/- mESCs to various 
tissues and organs can be explored.  
In Paper II, we generated a Sufu hypomorphic allele and described the effects of drastically 
reduced SUFU levels on embryo and organ development. Due to the crucial role of HH 
signalling activity in skin development, its aberrant activation in BCC formation, and the 
formation of basaloid skin changes in aged Sufu-/+ mice [36], we focused our investigations 
on skin initially. As in Paper I, here we have identified an additional role for SUFU in 
cartilage and bone formation. In this paper, we explored in depth the effects of reduced 
SUFU levels on skeletal development.  
We showed that different tissues have differential sensitivity towards SUFU reduction, 
however, the mechanisms of this tissue-specific response remains to be elucidated. Both in 
skin and in bone, KIF7 has been reported to have a dual role in HH signalling, suppressing 
the pathway in the absence of SUFU, on the one hand or promoting the dissociation of 
SUFU-GLI complexes, on the other, thus facilitating pathway activation [29,30]. It will be 
interesting to investigate the role of KIF7 in Sufuhypo/hypo tissues and to determine whether 
the observed effects are connected to levels of KIF7.  
As reported in our study we have not detected an increase in pathway activation in E16.5 
Sufuhypo/hypo skin, lung, or paws. Surprisingly, Gli1 mRNA levels were reduced in skin and 
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lung, yet the development of these organs was differentially affected by diminished SUFU 
levels. Since we analysed whole tissues and thus mRNA expression in the overall cell 
population, up or downregulation in a small critical cell population would not be detectable. 
This could be addressed by applying RNA in situ hybridisation, where expression can be 
assessed in individual cells. Additionally, it will be useful to address pathway activation in 
Sufuhypo/hypo skin, lung, and paw at various developmental stages as the time-points when 
SUFU is required presumably varies between tissues. Pathway activation can be visualised 
either by using RNA in situ hybridisation or crossing the hypomorphic allele to a reporter 
mouse, where for example lacZ is expressed under the Gli1 promoter. Furthermore, 
keratinocytes derived from Sufuhypo/hypo skin as well as cultures from affected limb and lung 
cell types would allow a more detailed analysis of the pathway activation, target gene 
expression and regulation of GLI proteins through SUFU.  
Besides skin and limb, a closer examination of the neural tube of in Sufuhypo/hypo mice would 
be of interest since HH signalling is crucial for patterning and closure of the neural tube 
[183] and in 27% of E18.5 embryos we observed exencephaly. SUFU plays a critical role in 
neural tube patterning as neuronal identity was found to be disturbed in Sufu-/- embryos 
[36].  
Finally, crossing of Sufuhypo/+ and Sufu-/+ mice would allow further evaluation of tissue 
specific dose-dependency on SUFU. 
In Paper III, we developed a transgenic mouse line in which expression of huLGR5 can be 
spatially and temporally regulated. We showed that initiation of huLGR5 expression in K5+ 
cells during embryogenesis, but not at early adulthood led to changes in skin morphology. 
While we detected huLGR5 in the basal layer of IFE in embryonic skin, expression in adult 
IFE was more irregular. It could thus be speculated that the induction of huLGR5 was 
higher during development than in young adults, explaining why initiation of huLGR5 
expression at P21 remained without morphological changes. However, why we observe the 
change in expression pattern remains unclear. The functionality of K5tTA in adult mice was 
previously confirmed crossing K5tTA transgenics to tetOlacZ reporter mice, detecting β-
galactosidase expression in most basal cells of the IFE [179]. Isolation of primary 
keratinocytes and the analyses of DNA methylation or histone H3 lysine 9/27 
trimethylation (H3K9Me3) would provide insight into possible silencing of the promoter 
region in adult skin.  
Primary keratinocytes also provide a tool for a more detailed assessment of the molecular 
effects of expressed huLGR5. As we demonstrated, skin of K5tTA;LGR5 exhibited 
increased levels of R-spondins, Wnt5a, and Gli1. Setting up an in vitro system would allow 
investigating the effects of canonical and non-canonical Wnt stimulation on keratinocyte 
differentiation and proliferation. Furthermore, as increased Gli1 levels suggest an 
involvement of HH signalling in the phenotype of huLGR5 overexpression, consequences 
of abolished HH signalling in K5tTA;LGR5 skin would be of interest. This could be 
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achieved by either crossing K5tTA;LGR5 mice to Gli1-lacZ homozygous animals, or 
treating huLGR5-expressing mice with the HH signalling inhibitor Gant61. 
As previously reported, high levels of LGR5 are found in various types of cancer for 
example in BCC [112] and colon cancer [184]. Thus, the TRE-LGR5 mouse can be used in 
combination with cancer models to gain further insight into the effects of overexpressed 
huLGR5 on cancer initiation and progression.  
In the preliminary study, we aimed to investigate whether deletion of Sufu in Lgr5+ cells 
can induce tumour formation. Our finding, in light of the tumour-initiating capacity of 
Ptch1-deficient Lgr5+ cells [107], indicates that the threshold of HH pathway activation 
required for inducing skin changes is not achieved by merely deleting Sufu. Similarly, Li et. 
al. [30] demonstrated that deletion of Ptch1 in basal cells of the skin results in BCC-like 
lesions whereas loss of Sufu leads to the development of basaloid follicular hamartomas 
(BFH), despite ectopic pathway activation in the IFE. This corroborates previous reports 
showing that the extent of HH activity determines the skin tumour phenotype [30,185]. The 
difference in skin phenotype in the study by Li et. al. [30] was attributed to the restriction of 
HH pathway activation through KIF7 in the absence of SUFU. Analysis of Lgr5Cre-
ERT2;Tomato;SufuFL/FL;Kif7FL/FL mice would provide insight into whether removal of KIF7 
would allow tumours to form.  
Likewise, a comparison of Lgr5+, Ptch1- or Sufu-deficient HF keratinocytes would provide 
a deeper understanding of differences in pathway activation, possible variations in target 
gene specificity and may unveil additional pathway regulators accounting for the distinct 
phenotypes evoked. As we demonstrated in Paper II, different tissues show a disparate 
sensitivity towards SUFU loss. Intriguingly, as deletion of SUFU in K14+ [30], but not in 
Lgr5+ (preliminary study) cells induces skin changes, it appears that even cells within the 
same tissue respond differentially to SUFU loss. This might be due to different niches the 
cells reside in [186] or due to intrinsic factors. Thus it would be interesting to isolate K14-
Cre;SufuFL/FL and Lgr5Cre-ERT2;Tomato;SufuFL/FL keratinocytes and analyse differences in 
response to Sufu inactivation. 
 
 
 
 

  33 
6 ACKNOWLEDGEMENTS 
 
Doing a PhD is a fascinating adventure full of challenges, excitement and joy, yet at times 
very strenuous, and exhausting. Having reached the end of this journey I would like to 
express my sincere gratitude to the people accompanying and supporting me during these 
years.  
First and foremost, I would like to thank my supervisor Stephan Teglund. I really appreciate 
that you always kept your door open, willingly listening to my ideas and thoughts and 
patiently answering all my questions. You encouraged me to form my own concepts, valued 
my suggestions and always trusted my capabilities.  
I would also like to express my gratitude to my co-supervisor Rune Toftgård, for giving me 
the opportunity to embark on this journey, the insightful discussions and scientific advices.  
I am also grateful to Dennis Roop for the opportunity to visit his lab for two months. I 
learned a lot during my stay, established collaborations and found new friends for life. 
Furthermore, I would like to extend a special thanks to all co-authors and collaborators, 
Karin Heby Henricson, Jens Henrik Norum, Marco Gerling, Ganna Bilousova, Raoul 
Kuiper, Björn Rozell, Maria Kasper, Åsa Bergström, Agneta Andersson, Cornelius 
Trünkle and Therese Sørlie, whose commitment, hard work and input made the publications 
in this thesis possible.  
During my time as a PhD student I have met so many wonderful people in the lab, who 
created an environment where I felt very welcome. We shared laughs, tears, fikas, struggles, 
failures and successes, good and bad moments - all your encouragement, support, help, 
sharing of knowledge and constant cheering contributed to my personal and scientific 
development. I am grateful for each and every one of you! Thank you!! 
A big thank you to all my friends, new and old, for curiously following my PhD journey. 
Being supportive at all times and especially for reminding me that there is life outside petri 
dishes and animal facilities.  
Last but not least I would like to express my deepest gratitude to Andreas and my family, for 
always believing in me, giving me a push in the right direction when needed and catching me 
when falling.  
 
 

  35 
7 REFERENCES 
 
1. Nüsslein-Volhard C, Wieschaus E. 
Mutations affecting segment number and 
polarity in Drosophila. Nature. 1980;287: 
795–801.  
2. McMahon AP, Ingham PW, Tabin CJ. 
Developmental roles and clinical 
significance of hedgehog signaling. Curr 
Top Dev Biol. 2003;53: 1–114.  
3. Petrova A, Celli A, Jacquet L, Dafou D, 
Crumrine D, Hupe M, et al. 3D 
In&nbsp;Vitro Model of a Functional 
Epidermal Permeability Barrier from 
Human Embryonic Stem Cells and 
Induced Pluripotent Stem Cells. Stem 
Cell Reports. The Authors; 2014;2: 675–
689. doi:10.1016/j.stemcr.2014.03.009 
4. Nieuwenhuis E, Hui CC. Hedgehog 
signaling and congenital malformations. 
Clinical Genetics. 2004;67: 193–208. 
doi:10.1111/j.1399-0004.2004.00360.x 
5. Teglund S, Toftgård R. Hedgehog beyond 
medulloblastoma and basal cell 
carcinoma. 2010;1805: 181–208. 
doi:10.1016/j.bbcan.2010.01.003 
6. Pak E, Segal RA. Hedgehog Signal 
Transduction: Key Players, Oncogenic 
Drivers, and Cancer Therapy. 
Developmental Cell. Elsevier Inc; 
2016;38: 333–344. 
doi:10.1016/j.devcel.2016.07.026 
7. Huangfu D, Liu A, Rakeman AS, Murcia 
NS, Niswander L, Anderson KV. 
Hedgehog signalling in the mouse 
requires intraflagellar transport proteins. 
Nature. 2003;426: 83–87. 
doi:10.1038/nature02061 
8. Singla V, Reiter JF. The primary cilium 
as the cell's antenna: Signaling at a 
sensory organelle. Science. American 
Association for the Advancement of 
Science; 2006;313: 629–633. 
doi:10.1126/science.1124534 
9. Briscoe J, Thérond PP. The mechanisms 
of Hedgehog signalling and its roles in 
development and disease. Nat Rev Mol 
Cell Biol. 2013;14: 416–429. 
doi:10.1038/nrm3598 
10. Varjosalo MM, Taipale JJ. Hedgehog: 
functions and mechanisms. Genes & 
Development. 2008;22: 2454–2472. 
doi:10.1101/gad.1693608 
11. Ingham PW, Nakano Y, Seger C. 
Mechanisms and functions of Hedgehog 
signalling across the metazoa. Nat Rev 
Genet. 2011;12: 393–406. 
doi:10.1038/nrg2984 
12. Ramsbottom SA, Pownall ME. 
Regulation of Hedgehog Signalling Inside 
and Outside the Cell. J Dev Biol. 
Multidisciplinary Digital Publishing 
Institute; 2016;4: 23. 
doi:10.3390/jdb4030023 
13. Ingham PW, McMahon AP. Hedgehog 
signaling in animal development: 
paradigms and principles. Genes & 
Development. Cold Spring Harbor Lab; 
2001;15: 3059–3087. 
doi:10.1101/gad.938601 
14. Tukachinsky H, Petrov K, Watanabe M, 
Salic A. Mechanism of inhibition of the 
tumor suppressor Patched by Sonic 
Hedgehog. Proc Natl Acad Sci USA. 
2016;113: E5866–E5875. 
doi:10.1073/pnas.1606719113 
15. Carpenter D, Stone DM, Brush J, Ryan 
A, Armanini M, Frantz G, et al. 
Characterization of two patched receptors 
for the vertebrate hedgehog protein 
family. Proc Natl Acad Sci USA. 
1998;95: 13630–13634.  
16. Incardona JP, Lee JH, Robertson CP, 
Enga K, Kapur RP, Roelink H. Receptor-
mediated endocytosis of soluble and 
membrane-tethered Sonic hedgehog by 
Patched-1. Proc Natl Acad Sci USA. 
National Acad Sciences; 2000;97: 12044–
12049. doi:10.1073/pnas.220251997 
17. Beachy PA, Hymowitz SG, Lazarus RA, 
Leahy DJ, Siebold C. Interactions 
between Hedgehog proteins and their 
binding partners come into view. Genes 
& Development. Cold Spring Harbor 
Lab; 2010;24: 2001–2012. 
doi:10.1101/gad.1951710 
18. Rohatgi R, Milenkovic L, Scott MP. 
Patched1 regulates hedgehog signaling at 
the primary cilium. Science. American 
Association for the Advancement of 
Science; 2007;317: 372–376. 
doi:10.1126/science.1139740 
19. Bijlsma MF, Spek CA, Zivkovic D, van 
de Water S, Rezaee F, Peppelenbosch 
MP. Repression of Smoothened by 
Patched-Dependent (Pro-)Vitamin D3 
Secretion. Scott M, editor. PLoS Biol. 
 36 
Public Library of Science; 2006;4: e232–
14. doi:10.1371/journal.pbio.0040232 
20. Dwyer JR, Sever N, Carlson M, Nelson 
SF, Beachy PA, Parhami F. Oxysterols 
are novel activators of the hedgehog 
signaling pathway in pluripotent 
mesenchymal cells. Journal of Biological 
Chemistry. American Society for 
Biochemistry and Molecular Biology; 
2007;282: 8959–8968. 
doi:10.1074/jbc.M611741200 
21. Yavari A, Nagaraj R, Owusu-Ansah E, 
Folick A, Ngo K, Hillman T, et al. Role 
of Lipid Metabolism in Smoothened 
Derepression in Hedgehog Signaling. 
Developmental Cell. Elsevier Ltd; 
2010;19: 54–65. 
doi:10.1016/j.devcel.2010.06.007 
22. Katoh Y, Katoh M. Hedgehog Target 
Genes: Mechanisms of Carcinogenesis 
Induced by Aberrant Hedgehog Signaling 
Activation. Curr Mol Med. 2009;9: 873–
886.  
23. Hui C-C, Angers S. Gli Proteins in 
Development and Disease. Annu Rev 
Cell Dev Biol. 2011;27: 513–537. 
doi:10.1146/annurev-cellbio-092910-
154048 
24. Vokes SA, Ji H, Wong WH, McMahon 
AP. A genome-scale analysis of the cis-
regulatory circuitry underlying sonic 
hedgehog-mediated patterning of the 
mammalian limb. Genes & Development. 
2008;22: 2651–2663. 
doi:10.1101/gad.1693008 
25. Whitington T, Jolma A, Taipale J. 
Beyond the balance of activator and 
repressor. Science Signaling. American 
Association for the Advancement of 
Science; 2011;4: pe29–pe29. 
doi:10.1126/scisignal.2002183 
26. Sasaki H, Hui C, Nakafuku M, Kondoh 
H. A binding site for Gli proteins is 
essential for HNF-3beta floor plate 
enhancer activity in transgenics and can 
respond to Shh in vitro. Development. 
1997;124: 1313–1322.  
27. Jeong Y. Distinct regulators of Shh 
transcription in the floor plate and 
notochord indicate separate origins for 
these tissues in the mouse node. 
Development. 2003;130: 3891–3902. 
doi:10.1242/dev.00590 
28. Dorn KV, Hughes CE, Rohatgi R. A 
Smoothened-Evc2 Complex Transduces 
the Hedgehog Signal at Primary Cilia. 
Developmental Cell. Elsevier Inc; 2012;: 
1–13. doi:10.1016/j.devcel.2012.07.004 
29. Hsu SHC, Zhang X, Yu C, Li ZJ, Wunder 
JS, Hui CC, et al. Kif7 promotes 
hedgehog signaling in growth plate 
chondrocytes by restricting the inhibitory 
function of Sufu. Development. 
2011;138: 3791–3801. 
doi:10.1242/dev.069492 
30. Li ZJ, Nieuwenhuis E, Nien W, Zhang X, 
Zhang J, Puviindran V, et al. Kif7 
regulates Gli2 through Sufu-dependent 
and -independent functions during skin 
development and tumorigenesis. 
Development. 2012;139: 4152–4161. 
doi:10.1242/dev.081190 
31. Goetz SC, Anderson KV. The primary 
cilium: a signalling centre during 
vertebrate development. Nat Rev Genet. 
2010;11: 331–344. doi:10.1038/nrg2774 
32. Law KKL, Makino S, Mo R, Zhang X, 
Puviindran V, Hui C-C. Antagonistic and 
cooperative actions of kif7 and sufu 
define graded intracellular gli activities in 
hedgehog signaling. PLoS ONE. 2012;7: 
e50193. 
doi:10.1371/journal.pone.0050193 
33. He M, Subramanian R, Bangs F, 
Omelchenko T, Liem KF, Kapoor TM, et 
al. The kinesin-4 protein Kif7 regulates 
mammalian Hedgehog signalling by 
organizing the cilium tip compartment. 
Nat Cell Biol. 2014;16: 663–672. 
doi:10.1038/ncb2988 
34. Chávez M, Ena S, Van Sande J, de 
Kerchove d’Exaerde A, Schurmans S, 
Schiffmann SN. Modulation of Ciliary 
Phosphoinositide Content Regulates 
Trafficking and Sonic Hedgehog 
Signaling Output. Developmental Cell. 
Elsevier Inc; 2015;34: 338–350. 
doi:10.1016/j.devcel.2015.06.016 
35. Garcia-Gonzalo FR, Phua SC, Roberson 
EC, Garcia G, Abedin M, Schurmans S, 
et al. Phosphoinositides Regulate Ciliary 
Protein Trafficking to Modulate 
Hedgehog Signaling. Developmental 
Cell. 2015;34: 400–409. 
doi:10.1016/j.devcel.2015.08.001 
36. Svärd J, Henricson KH, Persson-Lek M, 
Rozell B, Lauth M, Bergström Å, et al. 
Genetic Elimination of Suppressor of 
Fused Reveals an Essential Repressor 
Function in the Mammalian Hedgehog 
Signaling Pathway. Developmental Cell. 
2006;10: 187–197. 
doi:10.1016/j.devcel.2005.12.013 
37. Cooper AF, Yu KP, Brueckner M, 
  37 
Brailey LL, Johnson L, McGrath JM, et 
al. Cardiac and CNS defects in a mouse 
with targeted disruption of suppressor of 
fused. Development. The Company of 
Biologists Limited; 2005;132: 4407–
4417. doi:10.1242/dev.02021 
38. Goodrich LV. Altered Neural Cell Fates 
and Medulloblastoma in Mouse patched 
Mutants. Science. 1997;277: 1109–1113. 
doi:10.1126/science.277.5329.1109 
39. Kogerman P, Grimm T, Kogerman L, 
Krause D, Undén AB, Sandstedt B, et al. 
Mammalian suppressor-of-fused 
modulates nuclear-cytoplasmic shuttling 
of Gli-1. Nat Cell Biol. 1999;1: 312–319. 
doi:10.1038/13031 
40. Pearse RV, Collier LS, Scott MP, Tabin 
CJ. Vertebrate homologs of Drosophila 
suppressor of fused interact with the gli 
family of transcriptional regulators. 
Developmental Biology. 1999;212: 323–
336. doi:10.1006/dbio.1999.9335 
41. Stone DM, Murone M, Luoh S, Ye W, 
Armanini MP, Gurney A, et al. 
Characterization of the human suppressor 
of fused, a negative regulator of the zinc-
finger transcription factor Gli. Journal of 
Cell Science. 1999;112 ( Pt 23): 4437–
4448.  
42. Dunaeva M, Michelson P, Kogerman P, 
Toftgård R. Characterization of the 
physical interaction of Gli proteins with 
SUFU proteins. J Biol Chem. 2003;278: 
5116–5122. 
doi:10.1074/jbc.M209492200 
43. Merchant M, Vajdos FF, Ultsch M, Maun 
HR, Wendt U, Cannon J, et al. 
Suppressor of fused regulates Gli activity 
through a dual binding mechanism. 
Molecular and Cellular Biology. 
American Society for Microbiology; 
2004;24: 8627–8641. 
doi:10.1128/MCB.24.19.8627-8641.2004 
44. Ding Q, Fukami SI, Meng X, Nishizaki 
Y, Zhang X, Sasaki H, et al. Mouse 
suppressor of fused is a negative regulator 
of sonic hedgehog signaling and alters the 
subcellular distribution of Gli1. Current 
Biology. 1999;9: 1119–1122.  
45. Barnfield PC, Zhang X, 
Thanabalasingham V, Yoshida M, Hui C-
C. Negative regulation of Gli1 and Gli2 
activator function by Suppressor of fused 
through multiple mechanisms. 
Differentiation. 2005;73: 397–405. 
doi:10.1111/j.1432-0436.2005.00042.x 
46. Cherry AL, Finta C, Karlström M, Jin Q, 
Schwend T, Astorga-Wells J, et al. 
Structural basis of SUFU-GLI interaction 
in human Hedgehog signalling regulation. 
Acta Crystallogr D Biol Crystallogr. 
2013;69: 2563–2579. 
doi:10.1107/S0907444913028473 
47. Shi Q, Han Y, Jiang J. Suppressor of 
fused impedes Ci/Gli nuclear import by 
opposing Trn/Kapβ2 in Hedgehog 
signaling. Journal of Cell Science. 
2014;127: 1092–1103. 
doi:10.1242/jcs.142828 
48. Cheng SY, Bishop JM. Suppressor of 
Fused represses Gli-mediated 
transcription by recruiting the SAP18-
mSin3 corepressor complex. Proc Natl 
Acad Sci USA. National Acad Sciences; 
2002;99: 5442–5447. 
doi:10.1073/pnas.082096999 
49. Paces-Fessy M, Boucher D, Petit E, 
Paute-Briand S, Blanchet-Tournier M-F. 
The negative regulator of Gli, Suppressor 
of fused (Sufu), interacts with SAP18, 
Galectin3 and other nuclear proteins. 
Biochem J. Portland Press Limited; 
2004;378: 353–362. 
doi:10.1042/BJ20030786 
50. Lin C, Yao E, Wang K, Nozawa Y, 
Shimizu H, Johnson JR, et al. Regulation 
of Sufu activity by p66β and Mycbp 
provides new insight into vertebrate 
Hedgehog signaling. Genes & 
Development. Cold Spring Harbor Lab; 
2014;28: 2547–2563. 
doi:10.1101/gad.249425.114 
51. Zhang Z, Shen L, Law K, Zhang Z, Liu 
X, Hua H, et al. Suppressor of Fused 
chaperones Gli proteins to generate 
transcriptional responses to Sonic 
Hedgehog signaling. Molecular and 
Cellular Biology. American Society for 
Microbiology; 2016;: MCB.00421–16. 
doi:10.1128/MCB.00421-16 
52. Han Y, Shi Q, Jiang J. Multisite 
interaction with Sufu regulates Ci/Gli 
activity through distinct mechanisms in 
Hh signal transduction. Proc Natl Acad 
Sci USA. National Acad Sciences; 2015;: 
201421628. 
doi:10.1073/pnas.1421628112 
53. Pan Y, Bai CB, Joyner AL, Wang B. 
Sonic hedgehog signaling regulates Gli2 
transcriptional activity by suppressing its 
processing and degradation. Molecular 
and Cellular Biology. American Society 
for Microbiology; 2006;26: 3365–3377. 
doi:10.1128/MCB.26.9.3365-3377.2006 
 38 
54. Wang B, Fallon JF, Beachy PA. 
Hedgehog-regulated processing of Gli3 
produces an anterior/posterior repressor 
gradient in the developing vertebrate 
limb. Cell. 2000;100: 423–434.  
55. Wang C, Pan Y, Wang B. Suppressor of 
fused and Spop regulate the stability, 
processing and function of Gli2 and Gli3 
full-length activators but not their 
repressors. Development. 2010;137: 
2001–2009. doi:10.1242/dev.052126 
56. Humke EW, Dorn KV, Milenkovic L, 
Scott MP, Rohatgi R. The output of 
Hedgehog signaling is controlled by the 
dynamic association between Suppressor 
of Fused and the Gli proteins. Genes & 
Development. 2010;24: 670–682. 
doi:10.1101/gad.1902910 
57. Kise Y, Morinaka A, Teglund S, Miki H. 
Sufu recruits GSK3β for efficient 
processing of Gli3. BIOCHEMICAL 
AND BIOPHYSICAL RESEARCH 
COMMUNICATIONS. Elsevier Inc; 
2009;387: 569–574. 
doi:10.1016/j.bbrc.2009.07.087 
58. Chen MH, Wilson CW, Li YJ, Law KKL, 
Lu CS, Gacayan R, et al. Cilium-
independent regulation of Gli protein 
function by Sufu in Hedgehog signaling 
is evolutionarily conserved. Genes & 
Development. 2009;23: 1910–1928. 
doi:10.1101/gad.1794109 
59. Jia J, Kolterud Å, Zeng H, Hoover A, 
Teglund S, Toftgård R, et al. Suppressor 
of Fused inhibits mammalian Hedgehog 
signaling in the absence of cilia. 
Developmental Biology. 2009;330: 452–
460. doi:10.1016/j.ydbio.2009.04.009 
60. Makino S, Zhulyn O, Mo R, Puviindran 
V, Zhang X, Murata T, et al. T396I 
mutation of mouse Sufu reduces the 
stability and activity of Gli3 repressor. 
Fernandez-Zapico M, editor. PLoS ONE. 
Public Library of Science; 2015;10: 
e0119455. 
doi:10.1371/journal.pone.0119455 
61. Di Marcotullio L, Ferretti E, Greco A, De 
Smaele E, Po A, Sico MA, et al. Numb is 
a suppressor of Hedgehog signalling and 
targets Gli1 for Itch-dependent 
ubiquitination. Nat Cell Biol. 2006;8: 
1415–1423. doi:10.1038/ncb1510 
62. Lin C, Chen M-H, Yao E, Song H, 
Gacayan R, Hui C-C, et al. Differential 
regulation of Gli proteins by Sufu in the 
lung affects PDGF signaling and 
myofibroblast development. 
Developmental Biology. 2014;392: 324–
333. doi:10.1016/j.ydbio.2014.05.014 
63. Tukachinsky H, Lopez LV, Salic A. A 
mechanism for vertebrate Hedgehog 
signaling: recruitment to cilia and 
dissociation of SuFu-Gli protein 
complexes. The Journal of Cell Biology. 
2010;191: 415–428. 
doi:10.1083/jcb.201004108 
64. Chen Y, Yue S, Xie L, Pu X-H, Jin T, 
Cheng SY. Dual Phosphorylation of 
Suppressor of Fused (Sufu) by PKA and 
GSK3 beta Regulates Its Stability and 
Localization in the Primary Cilium. 
Journal of Biological Chemistry. 
American Society for Biochemistry and 
Molecular Biology; 2011;286: 13502–
13511. doi:10.1074/jbc.M110.217604 
65. Raducu M, Fung E, Serres S, Infante P, 
Barberis A, Fischer R, et al. SCF 
(Fbxl17) ubiquitylation of Sufu regulates 
Hedgehog signaling and medulloblastoma 
development. The EMBO Journal. 
EMBO Press; 2016;: e201593374. 
doi:10.15252/embj.201593374 
66. Tariki M, Wieczorek SA, Schneider P, 
Bänfer S, Veitinger S, Jacob R, et al. RIO 
kinase 3 acts as a SUFU-dependent 
positive regulator of Hedgehog signaling. 
Cellular Signalling. 2013;25: 2668–2675. 
doi:10.1016/j.cellsig.2013.08.037 
67. Wang Y, Li Y, Hu G, Huang X, Rao H, 
Xiong X, et al. Nek2A phosphorylates 
and stabilizes SuFu: A new strategy of 
Gli2/Hedgehog signaling regulatory. 
Cellular Signalling. 2016. 
doi:10.1016/j.cellsig.2016.06.010 
68. Cockburn K, Rossant J. Making the 
blastocyst: lessons from the mouse. J Clin 
Invest. 2010;120: 995–1003. 
doi:10.1172/JCI41229 
69. Posfai E, Tam OH, Rossant J. 
Mechanisms of Pluripotency In Vivo and 
In Vitro. 1st ed. Stem Cells in 
Development and Disease. Elsevier Inc; 
2014. pp. 1–37. doi:10.1016/B978-0-12-
416022-4.00001-9 
70. Saiz N, Plusa B. Early cell fate decisions 
in the mouse embryo. Reproduction. 
Society for Reproduction and Fertility; 
2013;145: R65–80. doi:10.1530/REP-12-
0381 
71. Gilbert SF. Early Mammalian 
Development. Sinauer Associates; 2000.  
72. Arnold SJ, Robertson EJ. Making a 
commitment: cell lineage allocation and 
  39 
axis patterning in the early mouse 
embryo. Nat Rev Mol Cell Biol. 2009;10: 
91–103. doi:10.1038/nrm2618 
73. Martin GR. Isolation of a pluripotent cell 
line from early mouse embryos cultured 
in medium conditioned by 
teratocarcinoma stem cells. Proc Natl 
Acad Sci USA. National Academy of 
Sciences; 1981;78: 7634–7638.  
74. Evans MJ, Kaufman MH. Establishment 
in culture of pluripotential cells from 
mouse embryos. Nature. 1981;292: 154–
156.  
75. Bryja V, Bonilla S, Arenas E. Derivation 
of mouse embryonic stem cells. Nat 
Protoc. 2006;1: 2082–2087. 
doi:10.1038/nprot.2006.355 
76. Arkell RM, Tam PPL. Initiating head 
development in mouse embryos: 
integrating signalling and transcriptional 
activity. Open Biology. 2012;2: 120030–
120030. doi:10.1098/rsob.120030 
77. Tam PP, Behringer RR. Mouse 
gastrulation: the formation of a 
mammalian body plan. Mech Dev. 
1997;68: 3–25.  
78. Loebel D, Watson CM, De Young A, 
Tam P. Lineage choice and differentiation 
in mouse embryos and embryonic stem 
cells. Developmental Biology. 2003;264: 
1–14. doi:10.1016/S0012-
1606(03)00390-7 
79. Rivera-Pérez JA, Hadjantonakis A-K. 
The Dynamics of Morphogenesis in the 
Early Mouse Embryo. Cold Spring 
Harbor Perspectives in Biology. Cold 
Spring Harbor Lab; 2015;7: a015867–18. 
doi:10.1101/cshperspect.a015867 
80. Litingtung Y, Chiang C. Control of Shh 
activity and signaling in the neural tube. 
Dev Dyn. 2000;219: 143–154. 
doi:10.1002/1097-
0177(2000)9999:9999<::AID-
DVDY1050>3.0.CO;2-Q 
81. van den Brink GR. Hedgehog Signaling 
in Development and Homeostasis of the 
Gastrointestinal Tract. Physiological 
Reviews. 2007;87: 1343–1375. 
doi:10.1152/physrev.00054.2006 
82. Blanpain C, Fuchs E. Epidermal 
homeostasis: a balancing act of stem cells 
in the skin. Nat Rev Mol Cell Biol. 
2009;10: 207–217. doi:10.1038/nrm2636 
83. Menon GK. New insights into skin 
structure: scratching the surface. 
Advanced Drug Delivery Reviews. 
2002;54: S3–S17.  
84. Kretzschmar K, Watt FM. Markers of 
epidermal stem cell subpopulations in 
adult mammalian skin. Cold Spring 
Harbor Perspectives in Medicine. Cold 
Spring Harbor Laboratory Press; 2014;4: 
a013631–a013631. 
doi:10.1101/cshperspect.a013631 
85. Forni MF, Trombetta-Lima M, Sogayar 
MC. Stem cells in embryonic skin 
development. Biol Res. 2012;45: 215–
222. doi:10.4067/S0716-
97602012000300003 
86. Fuchs E. Scratching the surface of skin 
development. Nature. 2007;445: 834–
842. doi:10.1038/nature05659 
87. Blanpain C, Fuchs E. Epidermal Stem 
Cells of the Skin. Annu Rev Cell Dev 
Biol. 2006;22: 339–373. 
doi:10.1146/annurev.cellbio.22.010305.1
04357 
88. Koster MI, Roop DR. Mechanisms 
Regulating Epithelial Stratification. Annu 
Rev Cell Dev Biol. 2007;23: 93–113. 
doi:10.1146/annurev.cellbio.23.090506.1
23357 
89. Fuchs E. Keratins and the skin. Annu Rev 
Cell Dev Biol. 1995;11: 123–153. 
doi:10.1146/annurev.cb.11.110195.00101
1 
90. Moll R, Divo M, Langbein L. The human 
keratins: biology and pathology. 
Histochem Cell Biol. 2008;129: 705–733. 
doi:10.1007/s00418-008-0435-6 
91. Rossant J, Tam PPL. Mouse 
Development. Gulf Professional 
Publishing; 2002.  
92. Candi E, Schmidt R, Melino G. The 
cornified envelope: a model of cell death 
in the skin. Nat Rev Mol Cell Biol. 
2005;6: 328–340. doi:10.1038/nrm1619 
93. Jaks V, Kasper M, Toftgård R. The hair 
follicle—a stem cell zoo. Experimental 
Cell Research. Elsevier Inc; 2010;316: 
1422–1428. 
doi:10.1016/j.yexcr.2010.03.014 
94. Lee J, Tumbar T. Hairy tale of signaling 
in hair follicle development and cycling. 
Seminars in Cell and Developmental 
Biology. Elsevier Ltd; 2012;: 1–11. 
doi:10.1016/j.semcdb.2012.08.003 
95. Duverger O, Morasso MI. Epidermal 
patterning and induction of different hair 
types during mouse embryonic 
 40 
development. Moody SA, editor. Birth 
Defect Res C. 2009;87: 263–272. 
doi:10.1002/bdrc.20158 
96. Huelsken J, Vogel R, Erdmann B, 
Cotsarelis G, Birchmeier W. beta-Catenin 
controls hair follicle morphogenesis and 
stem cell differentiation in the skin. Cell. 
2001;105: 533–545.  
97. Chiang C, Swan RZ, Grachtchouk M, 
Bolinger M, Litingtung Y, Robertson EK, 
et al. Essential role for Sonic hedgehog 
during hair follicle morphogenesis. 
Developmental Biology. 1999;205: 1–9. 
doi:10.1006/dbio.1998.9103 
98. St-Jacques B, Dassule HR, Karavanova I, 
Botchkarev VA, Li J, Danielian PS, et al. 
Sonic hedgehog signaling is essential for 
hair development. Current Biology. 
1998;8: 12–12. doi:10.1016/S0960-
9822(98)70443-9 
99. Jaks V, Barker N, Kasper M, van Es JH, 
Snippert HJ, Clevers H, et al. Lgr5 marks 
cycling, yet long-lived, hair follicle stem 
cells. Nat Genet. 2008;40: 1291–1299. 
doi:10.1038/ng.239 
100. Brownell I, Guevara E, Bai CB, Loomis 
CA, Joyner AL. Nerve-derived sonic 
hedgehog defines a niche for hair follicle 
stem cells capable of becoming epidermal 
stem cells. Cell Stem Cell. 2011;8: 552–
565. doi:10.1016/j.stem.2011.02.021 
101. van de Wetering M, Sancho E, Verweij 
C, de Lau W, Oving I, Hurlstone A, et al. 
The beta-catenin/TCF-4 complex imposes 
a crypt progenitor phenotype on 
colorectal cancer cells. Cell. 2002;111: 
241–250.  
102. Barker N, van Es JH, Kuipers J, Kujala P, 
van den Born M, Cozijnsen M, et al. 
Identification of stem cells in small 
intestine and colon by marker gene Lgr5. 
Nature. 2007;449: 1003–1007. 
doi:10.1038/nature06196 
103. Barker N, Huch M, Kujala P, van de 
Wetering M, Snippert HJ, van Es JH, et 
al. Lgr5+ve Stem Cells Drive Self-
Renewal in the Stomach and Build Long-
Lived Gastric Units In Vitro. Stem Cell. 
Elsevier Ltd; 2010;6: 25–36. 
doi:10.1016/j.stem.2009.11.013 
104. de Visser KE, Ciampricotti M, Michalak 
EM, Tan DW-M, Speksnijder EN, Hau 
C-S, et al. Developmental stage-specific 
contribution of LGR5 +cells to basal and 
luminal epithelial lineages in the 
postnatal mammary gland. J Pathol. 
2012;228: 300–309. 
doi:10.1002/path.4096 
105. Yee KK, Li Y, Redding KM, Iwatsuki K, 
Margolskee RF, Jiang P. Lgr5-EGFP 
Marks Taste Bud Stem/Progenitor Cells 
in Posterior Tongue. STEM CELLS. 
2013. doi:10.1002/stem.1338 
106. Barker N, Rookmaaker MB, Kujala P, Ng 
A, Leushacke M, Snippert H, et al. 
Lgr5+ve Stem/Progenitor Cells 
Contribute to Nephron Formation during 
Kidney Development. Cell Reports. 
2012;2: 540–552. 
doi:10.1016/j.celrep.2012.08.018 
107. Kasper M, Jaks V, Are A, Bergström Å, 
Schwäger A, Svärd J, et al. Wounding 
enhances epidermal tumorigenesis by 
recruiting hair follicle keratinocytes. 
pnasorg. 2011.  
108. Morita H, Mazerbourg S, Bouley DM, 
Luo C-W, Kawamura K, Kuwabara Y, et 
al. Neonatal lethality of LGR5 null mice 
is associated with ankyloglossia and 
gastrointestinal distension. Molecular and 
Cellular Biology. American Society for 
Microbiology; 2004;24: 9736–9743. 
doi:10.1128/MCB.24.22.9736-9743.2004 
109. Garcia MI, Ghiani M, Lefort A, Libert F, 
Strollo S, Vassart G. LGR5 deficiency 
deregulates Wnt signaling and leads to 
precocious Paneth cell differentiation in 
the fetal intestine. Cell Reports. 
2009;331: 58–67. 
doi:10.1016/j.ydbio.2009.04.020 
110. de Lau W, Barker N, Low TY, Koo B-K, 
Li VSW, Teunissen H, et al. Lgr5 
homologues associate with Wnt receptors 
and mediate R-spondin signalling. 
Nature. Nature Publishing Group; 
2011;476: 293–297. 
doi:10.1038/nature10337 
111. McClanahan T, Koseoglu S, Smith K, 
Grein J, Gustafson E, Black S, et al. 
Identification of overexpression of orphan 
G protein-coupled receptor GPR49 in 
human colon and ovarian primary tumors. 
Cancer Biol Ther. 2006;5: 419–426.  
112. Tanese K, Fukuma M, Yamada T, Mori 
T, Yoshikawa T, Watanabe W, et al. G-
Protein-Coupled Receptor GPR49 is Up-
regulated in Basal Cell Carcinoma and 
Promotes Cell Proliferation and Tumor 
Formation. The American Journal of 
Pathology. 2008;173: 835–843. 
doi:10.2353/ajpath.2008.071091 
113. Kazanskaya O, Glinka A, del Barco 
Barrantes I, Stannek P, Niehrs C, Wu W. 
R-Spondin2 is a secreted activator of 
  41 
Wnt/beta-catenin signaling and is 
required for Xenopus myogenesis. 
Developmental Cell. 2004;7: 525–534. 
doi:10.1016/j.devcel.2004.07.019 
114. Ohkawara B, Glinka A, Niehrs C. Rspo3 
binds syndecan 4 and induces Wnt/PCP 
signaling via clathrin-mediated 
endocytosis to promote morphogenesis. 
Developmental Cell. 2011;20: 303–314. 
doi:10.1016/j.devcel.2011.01.006 
115. Carmon KS, Gong X, Lin Q, Thomas A, 
Liu Q. R-spondins function as ligands of 
the orphan receptors LGR4 and LGR5 to 
regulate Wnt/beta-catenin signaling. Proc 
Natl Acad Sci USA. 2011;108: 11452–
11457. doi:10.1073/pnas.1106083108 
116. Glinka A, Dolde C, Kirsch N, Huang Y-
L, Kazanskaya O, Ingelfinger D, et al. 
LGR4 and LGR5 are R-spondin receptors 
mediating Wnt/β-catenin and Wnt/PCP 
signalling. EMBO Rep. Nature 
Publishing Group; 2011;12: 1055–1061. 
doi:10.1038/embor.2011.175 
117. Hao H-X, Xie Y, Zhang Y, Charlat O, 
Oster E, Avello M, et al. ZNRF3 
promotes Wnt receptor turnover in an R-
spondin-sensitive manner. Nature. Nature 
Publishing Group; 2012;485: 195–200. 
doi:10.1038/nature11019 
118. Gilbert SF. Osteogenesis: The 
Development of Bones. Sinauer 
Associates; 2000.  
119. Behringer R, Gertsenstein M, Nagy KV, 
Nagy A. Manipulating the Mouse 
Embryo. 2014.  
120. Berendsen AD, Olsen BR. Bone 
development. Bone. Elsevier Inc; 
2015;80: 14–18. 
doi:10.1016/j.bone.2015.04.035 
121. Long F, Ornitz DM. Development of the 
endochondral skeleton. Cold Spring 
Harbor Perspectives in Biology. Cold 
Spring Harbor Lab; 2013;5: a008334–
a008334. 
doi:10.1101/cshperspect.a008334 
122. Kronenberg HM. Developmental 
regulation of the growth plate. Nature. 
2003;423: 332–336. 
doi:10.1038/nature01657 
123. Day TF, Yang Y. Wnt and hedgehog 
signaling pathways in bone development. 
J Bone Joint Surg Am. 2008;90 Suppl 1: 
19–24. doi:10.2106/JBJS.G.01174 
124. Yang J, Andre P, Ye L, Yang Y-Z. The 
Hedgehog signalling pathway in bone 
formation. Int J Oral Sci. 2015. 
doi:10.1038/ijos.2015.14 
125. St-Jacques B, Hammerschmidt M, 
McMahon AP. Indian hedgehog signaling 
regulates proliferation and differentiation 
of chondrocytes and is essential for bone 
formation. Genes & Development. 
1999;13: 2072–2086.  
126. Tickle C. Making digit patterns in the 
vertebrate limb. Nat Rev Mol Cell Biol. 
2005;7: 45–53. doi:10.1038/nrm1830 
127. Delgado I, Torres M. Gradients, waves 
and timers, an overview of limb 
patterning models. Seminars in Cell and 
Developmental Biology. 2016. 
doi:10.1016/j.semcdb.2015.12.016 
128. Zhu J, Nakamura E, Nguyen M-T, Bao X, 
Akiyama H, Mackem S. Uncoupling 
Sonic Hedgehog Control of Pattern and 
Expansion of the Developing Limb Bud. 
Developmental Cell. 2008;14: 624–632. 
doi:10.1016/j.devcel.2008.01.008 
129. Zhulyn O, Li D, Deimling S, Vakili NA, 
Mo R, Puviindran V, et al. A Switch from 
Low to High Shh Activity Regulates 
Establishment of Limb Progenitors and 
Signaling Centers. Developmental Cell. 
2014. doi:10.1016/j.devcel.2014.03.002 
130. Welscher te P, Zuniga A, Kuijper S, 
Drenth T, Goedemans HJ, Meijlink F, et 
al. Progression of vertebrate limb 
development through SHH-mediated 
counteraction of GLI3. Science. 
American Association for the 
Advancement of Science; 2002;298: 827–
830. doi:10.1126/science.1075620 
131. Roessler E, Belloni E, Gaudenz K, Jay P, 
Berta P, Scherer SW, et al. Mutations in 
the human Sonic Hedgehog gene cause 
holoprosencephaly. Nat Genet. 1996;14: 
357–360. doi:10.1038/ng1196-357 
132. Belloni E, Muenke M, Roessler E, 
Traverso G, Siegel-Bartelt J, Frumkin A, 
et al. Identification of Sonic hedgehog as 
a candidate gene responsible for 
holoprosencephaly. Nat Genet. 1996;14: 
353–356. doi:10.1038/ng1196-353 
133. Dubourg C, Bendavid C, Pasquier L, 
Henry C, Odent S, David V. 
Holoprosencephaly. Orphanet J Rare Dis. 
2007;2: 8. doi:10.1186/1750-1172-2-8 
134. Ming JE, Kaupas ME, Roessler E, 
Brunner HG, Golabi M, Tekin M, et al. 
Mutations in PATCHED-1, the receptor 
for SONIC HEDGEHOG, are associated 
with holoprosencephaly. Hum Genet. 
 42 
Springer-Verlag; 2002;110: 297–301. 
doi:10.1007/s00439-002-0695-5 
135. Hahn H, Wicking C, Zaphiropoulos PG, 
Gailani MR, Shanley S, Chidambaram A, 
et al. Mutations of the human homolog of 
Drosophila patched in the nevoid basal 
cell carcinoma syndrome. Cell. 1996;85: 
841–851.  
136. Johnson RL, Rothman AL, Xie JW, 
Goodrich LV, Bare JW, Bonifas JM, et 
al. Human homolog of patched, a 
candidate gene for the basal cell nevus 
syndrome. Science. 1996;272: 1668–
1671.  
137. Gorlin RJ. Nevoid basal cell carcinoma 
(Gorlin) syndrome. Genet Med. 2004;6: 
530–539. 
doi:10.1097/01.GIM.0000144188.15902.
C4 
138. Smith MJ, Beetz C, Williams SG, 
Bhaskar SS, O'Sullivan J, Anderson B, et 
al. Germline mutations in SUFU cause 
Gorlin syndrome-associated childhood 
medulloblastoma and redefine the risk 
associated with PTCH1 mutations. 
Journal of Clinical Oncology. American 
Society of Clinical Oncology; 2014;32: 
4155–4161. 
doi:10.1200/JCO.2014.58.2569 
139. Pastorino L, Ghiorzo P, Nasti S, 
Battistuzzi L, Cusano R, Marzocchi C, et 
al. Identification of a SUFUgermline 
mutation in a family with Gorlin 
syndrome. Am J Med Genet. 2009;149A: 
1539–1543. doi:10.1002/ajmg.a.32944 
140. Biesecker LG. What you can learn from 
one gene: GLI3. Journal of Medical 
Genetics. BMJ Publishing Group Ltd; 
2006;43: 465–469. 
doi:10.1136/jmg.2004.029181 
141. Gao B, Guo J, She C, Shu A, Yang M, 
Tan Z, et al. Mutations in IHH, encoding 
Indian hedgehog, cause brachydactyly 
type A-1. Nat Genet. 2001;28: 386–388. 
doi:10.1038/ng577 
142. Hellemans J, Coucke PJ, Giedion A, De 
Paepe A, Kramer P, Beemer F, et al. 
Homozygous mutations in IHH cause 
acrocapitofemoral dysplasia, an 
autosomal recessive disorder with cone-
shaped epiphyses in hands and hips. The 
American Journal of Human Genetics. 
2003;72: 1040–1046.  
143. Epstein EH. Basal cell carcinomas: attack 
of the hedgehog. Nat Rev Cancer. 2008;8: 
743–754. doi:10.1038/nrc2503 
144. Reifenberger J, Wolter M, Knobbe CB, 
Köhler B, Schönicke A, Scharwächter C, 
et al. Somatic mutations in the PTCH, 
SMOH, SUFUHand TP53genes in 
sporadic basal cell carcinomas. British 
Journal of Dermatology. 2005;152: 43–
51. doi:10.1111/j.1365-
2133.2005.06353.x 
145. Aavikko M, Li S-P, Saarinen S, Alhopuro 
P, Kaasinen E, Morgunova E, et al. Loss 
of SUFU Function in Familial Multiple 
Meningioma. The American Journal of 
Human Genetics. The American Society 
of Human Genetics; 2012;91: 520–526. 
doi:10.1016/j.ajhg.2012.07.015 
146. Schulman JM, Oh DH, Sanborn JZ, 
Pincus L, McCalmont TH, Cho RJ. 
Multiple Hereditary Infundibulocystic 
Basal Cell Carcinoma Syndrome 
Associated With a Germline SUFU 
Mutation. JAMA Dermatol. 2015;: 1–5. 
doi:10.1001/jamadermatol.2015.4233 
147. Taylor MD, Liu L, Raffel C, Hui C-C, 
Mainprize TG, Zhang X, et al. Mutations 
in SUFU predispose to medulloblastoma. 
Nat Genet. 2002;31: 306–310. 
doi:10.1038/ng916 
148. Cohen PR, Kurzrock R. Merkel Cell 
Carcinoma with a Suppressor of Fused 
(SUFU) Mutation: Case Report and 
Potential Therapeutic Implications. 
Dermatol Ther (Heidelb). Springer 
Healthcare; 2015;5: 129–143. 
doi:10.1007/s13555-015-0074-5 
149. Sekulic A, Migden MR, Oro AE, Dirix L, 
Lewis KD, Hainsworth JD, et al. Efficacy 
and safety of vismodegib in advanced 
basal-cell carcinoma. N Engl J Med.  
Massachusetts Medical Society; 
2012;366: 2171–2179. 
doi:10.1056/NEJMoa1113713 
150. Sekulic A, Hoff Von D. Bench to Bedside 
Hedgehog Pathway Inhibition. Elsevier; 
2016;: 1–1. 
doi:10.1016/j.cell.2016.02.021 
151. Kish T, Corry L. Sonidegib (Odomzo) for 
the Systemic Treatment of Adults With 
Recurrent, Locally Advanced Basal Cell 
Skin Cancer. P T. MediMedia, USA; 
2016;41: 322–325.  
152. Atwood SX, Sarin KY, Whitson RJ, Li 
JR, Kim G, Rezaee M, et al. Smoothened 
variants explain the majority of drug 
resistance in basal cell carcinoma. Cancer 
Cell. 2015;27: 342–353. 
doi:10.1016/j.ccell.2015.02.002 
153. Lauth M, Bergström Å, Shimokawa T, 
  43 
Toftgård R. Inhibition of GLI-mediated 
transcription and tumor cell growth by 
small-molecule antagonists. Proc Natl 
Acad Sci USA. National Acad Sciences; 
2007;104: 8455–8460. 
doi:10.1073/pnas.0609699104 
154. Gonnissen A, Isebaert S, Haustermans K. 
Targeting the Hedgehog signaling 
pathway in cancer: beyond Smoothened. 
Oncotarget. Impact Journals; 2015;6: 
13899–13913. 
doi:10.18632/oncotarget.4224 
155. De Los Angeles A, Ferrari F, Xi R, 
Fujiwara Y, Benvenisty N, Deng H, et al. 
Hallmarks of pluripotency. Nature. 
2015;525: 469–478. 
doi:10.1038/nature15515 
156. Niwa H. How is pluripotency determined 
and maintained? Development. 2007;134: 
635–646. doi:10.1242/dev.02787 
157. Bradley A, Evans M, Kaufman MH, 
Robertson E. Formation of germ-line 
chimaeras from embryo-derived 
teratocarcinoma cell lines. Nature. 
1984;309: 255–256.  
158. Nishikawa S-I, Jakt LM, Era T. 
Embryonic stem-cell culture as a tool for 
developmental cell biology. Nat Rev Mol 
Cell Biol. 2007;8: 502–507. 
doi:10.1038/nrm2189 
159. Capecchi MR. Generating mice with 
targeted mutations. Nat Med. 2001;7: 
1086–1090. doi:10.1038/nm1001-1086 
160. Smithies O. Forty years with homologous 
recombination. Nat Med. 2001;7: 1083–
1086. doi:10.1038/nm1001-1083 
161. Turner DA, Baillie-Johnson P, Martinez 
Arias A. Organoids and the genetically 
encoded self-assembly of embryonic stem 
cells. Bioessays. 2015;: n/a–n/a. 
doi:10.1002/bies.201500111 
162. Bratt-Leal AM, Carpenedo RL, McDevitt 
TC. Engineering the embryoid body 
microenvironment to direct embryonic 
stem cell differentiation. Biotechnol Prog. 
2009;25: 43–51. doi:10.1002/btpr.139 
163. Wesselschmidt RL. The teratoma assay: 
an in vivo assessment of pluripotency. 
Methods Mol Biol. 2011;767: 231–241. 
doi:10.1007/978-1-61779-201-4_17 
164. Ulbright TM. Germ cell tumors of the 
gonads: a selective review emphasizing 
problems in differential diagnosis, newly 
appreciated, and controversial issues. 
Mod Pathol. 2005;18: S61–S79. 
doi:10.1038/modpathol.3800310 
165. Takahashi K, Yamanaka S. Induction of 
Pluripotent Stem Cells from Mouse 
Embryonic and Adult Fibroblast Cultures 
by Defined Factors. Cell. 2006;126: 663–
676. doi:10.1016/j.cell.2006.07.024 
166. Seah Y, EL Farran C, Warrier T, Xu J, 
Loh Y-H. Induced Pluripotency and Gene 
Editing in Disease Modelling: 
Perspectives and Challenges. IJMS. 
Multidisciplinary Digital Publishing 
Institute; 2015;16: 28614–28634. 
doi:10.3390/ijms161226119 
167. Rossant J. Human embryology: 
Implantation barrier overcome. Nature. 
2016;: 1–2. doi:10.1038/nature17894 
168. Evans MJ. The cultural mouse. Nat Med. 
2001;7: 1081–1083. 
doi:10.1038/nm1001-1081 
169. Schwartzberg PL, Goff SP, Robertson EJ. 
Germ-line transmission of a c-abl 
mutation produced by targeted gene 
disruption in ES cells. Science. 1989;246: 
799–803.  
170. Zijlstra M, Li E, Sajjadi F, Subramani S, 
Jaenisch R. Germ-line transmission of a 
disrupted beta 2-microglobulin gene 
produced by homologous recombination 
in embryonic stem cells. Nature. Nature 
Publishing Group; 1989;342: 435–438. 
doi:10.1038/342435a0 
171. Koller BH, Hagemann LJ, Doetschman T, 
Hagaman JR, Huang S, Williams PJ, et 
al. Germ-line transmission of a planned 
alteration made in a hypoxanthine 
phosphoribosyltransferase gene by 
homologous recombination in embryonic 
stem cells. Proc Natl Acad Sci USA. 
National Academy of Sciences; 1989;86: 
8927–8931.  
172. Thompson S, Clarke AR, Pow AM, 
Hooper ML, Melton DW. Germ line 
transmission and expression of a 
corrected HPRT gene produced by gene 
targeting in embryonic stem cells. Cell. 
1989;56: 313–321.  
173. Sauer B. Inducible Gene Targeting in 
Mice Using the Cre&sol;lox System. 
1998;: 1–12.  
174. Feil REA. Regulation of Cre 
Recombinase Activity by Mutated 
Estrogen Receptor Ligand-Binding 
Domains. 1997;: 1–6.  
175. Soriano P. Generalized lacZ expression 
with the ROSA26 Cre reporter strain. Nat 
 44 
Genet. 1999;21: 70–71. doi:10.1038/5007 
176. Madisen L, Zwingman TA, Sunkin SM, 
Oh SW, Zariwala HA, Gu H, et al. A 
robust and high-throughput Cre reporting 
and characterization system for the whole 
mouse brain. Nat Neurosci. Nature 
Publishing Group; 2009;13: 133–140. 
doi:10.1038/nn.2467 
177. Baker DJ. Hypomorphic mice. Methods 
Mol Biol. 2011;693: 233–244. 
doi:10.1007/978-1-60761-974-1_13 
178. Sprengel R, Hasan MT. Tetracycline-
controlled genetic switches. Handb Exp 
Pharmacol. Berlin, Heidelberg: Springer 
Berlin Heidelberg; 2007;178: 49–72. 
doi:10.1007/978-3-540-35109-2_3 
179. Diamond I, Owolabi T, Marco M, Lam C, 
Glick A. Conditional gene expression in 
the epidermis of transgenic mice using 
the tetracycline-regulated transactivators 
tTA and rTA linked to the keratin 5 
promoter. J Invest Dermatol. Elsevier; 
2000;115: 788–794. doi:10.1046/j.1523-
1747.2000.00144.x 
180. Moullan N, Mouchiroud L, Wang X, Ryu 
D, Williams EG, Mottis A, et al. 
Tetracyclines Disturb Mitochondrial 
Function across Eukaryotic Models: A 
Call for Caution in Biomedical Research. 
Cell Reports. The Authors; 2015;10: 
1681–1691. 
doi:10.1016/j.celrep.2015.02.034 
181. Bhatia A, Singh B, Amarji B, Katare OP. 
Tamoxifen-loaded liposomal topical 
formulation arrests hair growth in mice. 
British Journal of Dermatology. 
2010;163: 412–415. doi:10.1111/j.1365-
2133.2010.09772.x 
182. Maye P, Becker S, Siemen H, Thorne J, 
Byrd N, Carpentino J, et al. Hedgehog 
signaling is required for the 
differentiation of ES cells into 
neurectoderm. Developmental Biology. 
2004;265: 276–290. 
doi:10.1016/j.ydbio.2003.09.027 
183. Dessaud E, McMahon AP, Briscoe J. 
Pattern formation in the vertebrate neural 
tube: a sonic hedgehog morphogen-
regulated transcriptional network. 
Development. The Company of 
Biologists Ltd; 2008;135: 2489–2503. 
doi:10.1242/dev.009324 
184. Liu Z, Dai W, Jiang L, Cheng Y. Over-
expression of LGR5 correlates with poor 
survival of colon cancer in mice as well 
as in patients. Neoplasma. 2014;61: 177–
185. doi:10.4149/neo_2014_016 
185. Grachtchouk V, Grachtchouk M, Lowe L, 
Johnson T, Wei L, Wang A, et al. The 
magnitude of hedgehog signaling activity 
defines skin tumor phenotype. The 
EMBO Journal. 2003;22: 2741–2751. 
doi:10.1093/emboj/cdg271 
186. Peterson SC, Eberl M, Vagnozzi AN, 
Belkadi A, Veniaminova NA, Verhaegen 
ME, et al. Basal Cell Carcinoma 
Preferentially Arises from Stem Cells 
within Hair Follicle and Mechanosensory 
Niches. Cell Stem Cell. 2015;16: 400–
412. doi:10.1016/j.stem.2015.02.006 
 
